{"id":2302,"date":"2025-06-16T11:57:13","date_gmt":"2025-06-16T01:57:13","guid":{"rendered":"https:\/\/braintechaustralia.com.au\/2025\/?page_id=2302"},"modified":"2026-06-15T16:17:02","modified_gmt":"2026-06-15T06:17:02","slug":"speakers","status":"publish","type":"page","link":"https:\/\/braintechaustralia.com.au\/2025\/speakers\/","title":{"rendered":"Speakers"},"content":{"rendered":"

[et_pb_section fb_built=”1″ _builder_version=”4.27.4″ _module_preset=”default” use_background_color_gradient=”on” background_color_gradient_direction=”90deg” background_color_gradient_stops=”rgba(0,41,51,0.48) 0%|rgba(138,188,187,0.85) 60%|rgba(0,41,51,0.48) 100%” background_color_gradient_overlays_image=”on” background_image=”https:\/\/silverfutures.com.au\/wp-content\/uploads\/water.jpg” custom_margin=”0px||||false|false” custom_padding=”10px||||false|false” bottom_divider_style=”wave” bottom_divider_color=”#FFFFFF” bottom_divider_height=”50px” bottom_divider_flip=”horizontal” bottom_divider_arrangement=”above_content” locked=”off” global_colors_info=”{}”][et_pb_row column_structure=”3_4,1_4″ use_custom_gutter=”on” gutter_width=”2″ make_equal=”on” _builder_version=”4.27.4″ _module_preset=”default” custom_css_main_element=”align-items: center;” global_colors_info=”{}”][et_pb_column type=”3_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.27.6″ _module_preset=”default” header_font=”||||||||” header_2_font=”|||on|||||” header_2_text_color=”#FFFFFF” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″]<\/p>\n

2025 Speakers<\/span><\/h2>\n

[\/et_pb_text][\/et_pb_column][et_pb_column type=”1_4″ _builder_version=”4.27.4″ _module_preset=”default” background_enable_image=”off” background_size=”contain” global_colors_info=”{}”][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ disabled_on=”on|on|on” module_id=”michael-berk” _builder_version=”4.27.4″ _module_preset=”default” custom_margin=”||0px||false|false” custom_padding=”||0px||false|false” disabled=”on” global_colors_info=”{}”][et_pb_row column_structure=”1_4,3_4″ use_custom_gutter=”on” gutter_width=”2″ _builder_version=”4.27.4″ _module_preset=”default” custom_margin=”0px||0px||true|false” custom_padding=”0px||0px||true|false” global_colors_info=”{}”][et_pb_column type=”1_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_image src=”https:\/\/braintechaustralia.com.au\/2025\/wp-content\/uploads\/2025\/06\/braintech-2025-speakers-michael-berk-500px.jpg” alt=”Michael Berk” title_text=”Michael Berk” _builder_version=”4.27.4″ _module_preset=”default” border_width_all=”5px” border_color_all=”#CCE8E9″ global_colors_info=”{}”][\/et_pb_image][\/et_pb_column][et_pb_column type=”3_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” text_font=”|600|||||||” text_text_color=”#002933″ header_3_font=”|700||on|||||” header_3_text_color=”#DC6B5B” custom_margin=”||0px||false|false” custom_padding=”||0px||false|false” global_colors_info=”{}”]<\/p>\n

Professor Michael Berk<\/h3>\n

Chair of Psychiatry, Deakin University[\/et_pb_text][et_pb_social_media_follow _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_social_media_follow_network social_network=”linkedin” url=”https:\/\/www.linkedin.com\/in\/michael-berk-93656132″ _builder_version=”4.27.4″ _module_preset=”default” background_color=”#DC6B5B” background_enable_color=”on” global_colors_info=”{}” icon_color__hover_enabled=”off|desktop” background__hover_enabled=”on|hover” background_color__hover=”#8ABCBB” background_enable_color__hover=”on” follow_button=”off” url_new_window=”on”]linkedin[\/et_pb_social_media_follow_network][\/et_pb_social_media_follow][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”]Professor Michael Berk is currently a NHMRC L3 research Fellow and is Alfred Deakin Chair of Psychiatry at Deakin University and Barwon Health, where he heads the Institute for Innovation in Mental and Physical Health and Clinical Translation (IMPACT). He is also an Honorary Professorial Research fellow in the Department of Psychiatry, the Florey Institute for Neuroscience and Mental Health and Orygen Youth Health at Melbourne University, as well as in the School of Public Health and Preventive Medicine at Monash University. He has published over 1600 papers and is listed by Thompson Reuters ISI as highly cited (2015-2023). His major interests are in the discovery and implementation of novel therapies.[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ module_id=”adele-barnard” _builder_version=”4.27.4″ _module_preset=”default” custom_margin=”||0px||false|false” custom_padding=”||0px||false|false” locked=”off” global_colors_info=”{}”][et_pb_row column_structure=”1_4,3_4″ use_custom_gutter=”on” gutter_width=”2″ _builder_version=”4.27.4″ _module_preset=”default” custom_margin=”0px||0px||true|false” custom_padding=”0px||0px||true|false” global_colors_info=”{}”][et_pb_column type=”1_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_image src=”https:\/\/braintechaustralia.com.au\/2025\/wp-content\/uploads\/2025\/09\/braintech-2025-speakers-adele-barnard-500px.jpg” alt=”Adele Barnard” title_text=”Adele Barnard” _builder_version=”4.27.4″ _module_preset=”default” border_width_all=”5px” border_color_all=”#CCE8E9″ global_colors_info=”{}”][\/et_pb_image][\/et_pb_column][et_pb_column type=”3_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” text_font=”|600|||||||” text_text_color=”#002933″ header_3_font=”|700||on|||||” header_3_text_color=”#DC6B5B” custom_margin=”||0px||false|false” custom_padding=”||0px||false|false” global_colors_info=”{}”]<\/p>\n

Adele Barnard<\/h3>\n

Clinical Research Director, Nutromics<\/p>\n

[\/et_pb_text][et_pb_social_media_follow _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_social_media_follow_network social_network=”linkedin” url=”https:\/\/www.linkedin.com\/in\/adelebarnard” _builder_version=”4.27.4″ _module_preset=”default” background_color=”#DC6B5B” background_enable_color=”on” global_colors_info=”{}” icon_color__hover_enabled=”off|desktop” background__hover_enabled=”on|hover” background_color__hover=”#8ABCBB” background_enable_color__hover=”on” follow_button=”off” url_new_window=”on”]linkedin[\/et_pb_social_media_follow_network][\/et_pb_social_media_follow][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”]Adele Barnard combines a PhD in Immunology with almost 20 years of experience in neuromodulation, having contributed to the development of some of the earliest waveforms and IPG systems in the mid-2000s. With extensive expertise in managing clinical trials in both the medical device and pharmacology sectors, she has led clinical research across Australia and held executive roles in prominent US companies, including Nevro and Abbott. She headed up a portfolio of clinical trials at Veritus Research in Australia. She also serves on human research ethics boards for medical device studies and consults to biotech companies, providing insights into the Australian regulatory landscape.[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ module_id=”alexandra-brassert” _builder_version=”4.27.4″ _module_preset=”default” custom_margin=”||0px||false|false” custom_padding=”||0px||false|false” locked=”off” global_colors_info=”{}”][et_pb_row column_structure=”1_4,3_4″ use_custom_gutter=”on” gutter_width=”2″ _builder_version=”4.27.4″ _module_preset=”default” custom_margin=”0px||0px||true|false” custom_padding=”0px||0px||true|false” global_colors_info=”{}”][et_pb_column type=”1_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_image src=”https:\/\/braintechaustralia.com.au\/2025\/wp-content\/uploads\/2025\/09\/braintech-2025-speakers-alexandra-brassert-500px.jpg” alt=”Alexandra Brassert” title_text=”Alexandra Brassert” _builder_version=”4.27.4″ _module_preset=”default” border_width_all=”5px” border_color_all=”#CCE8E9″ global_colors_info=”{}”][\/et_pb_image][\/et_pb_column][et_pb_column type=”3_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” text_font=”|600|||||||” text_text_color=”#002933″ header_3_font=”|700||on|||||” header_3_text_color=”#DC6B5B” custom_margin=”||0px||false|false” custom_padding=”||0px||false|false” global_colors_info=”{}”]<\/p>\n

Alexandra Brassert<\/h3>\n

Senior Manager, Concussion Clinic, Murdoch Children\u2019s Research Institute<\/p>\n

[\/et_pb_text][et_pb_social_media_follow _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_social_media_follow_network social_network=”linkedin” url=”https:\/\/www.linkedin.com\/in\/lotlexa” _builder_version=”4.27.4″ _module_preset=”default” background_color=”#DC6B5B” background_enable_color=”on” global_colors_info=”{}” icon_color__hover_enabled=”off|desktop” background__hover_enabled=”on|hover” background_color__hover=”#8ABCBB” background_enable_color__hover=”on” follow_button=”off” url_new_window=”on”]linkedin[\/et_pb_social_media_follow_network][\/et_pb_social_media_follow][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”]Alex Brassert is an innovation and commercialisation expert at the Murdoch Children\u2019s Research Institute (MCRI), with a proven track record of transforming digital health and medical research innovations into market-ready solutions. With expertise in health system policy, business strategy, and partnerships, Alex enables researchers and startups navigate the pathway from concept to commercial impact. She leads the commercialisation of the Concussion Clinic within MCRI\u2019s Brain and Mind group and serves on the ANDHealth+ Industry Advisory Panel.[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ disabled_on=”off|off|off” module_id=”michelle-burke” _builder_version=”4.27.4″ _module_preset=”default” custom_margin=”||0px||false|false” custom_padding=”||0px||false|false” locked=”off” global_colors_info=”{}”][et_pb_row column_structure=”1_4,3_4″ use_custom_gutter=”on” gutter_width=”2″ _builder_version=”4.27.4″ _module_preset=”default” custom_margin=”0px||0px||true|false” custom_padding=”0px||0px||true|false” global_colors_info=”{}”][et_pb_column type=”1_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_image src=”https:\/\/braintechaustralia.com.au\/2025\/wp-content\/uploads\/2025\/09\/braintech-2025-speakers-michelle-burke-500px.jpg” alt=”Michelle Burke” title_text=”Michelle Burke” _builder_version=”4.27.4″ _module_preset=”default” border_width_all=”5px” border_color_all=”#CCE8E9″ global_colors_info=”{}”][\/et_pb_image][\/et_pb_column][et_pb_column type=”3_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” text_font=”|600|||||||” text_text_color=”#002933″ header_3_font=”|700||on|||||” header_3_text_color=”#DC6B5B” custom_margin=”||0px||false|false” custom_padding=”||0px||false|false” global_colors_info=”{}”]<\/p>\n

Michelle Burke<\/h3>\n

Chair, Cell Therapies Pty Ltd[\/et_pb_text][et_pb_social_media_follow _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_social_media_follow_network social_network=”linkedin” url=”https:\/\/www.linkedin.com\/in\/michelle-burke-15061915\/” _builder_version=”4.27.4″ _module_preset=”default” background_color=”#DC6B5B” background_enable_color=”on” global_colors_info=”{}” icon_color__hover_enabled=”off|desktop” background__hover_enabled=”on|hover” background_color__hover=”#8ABCBB” background_enable_color__hover=”on” follow_button=”off” url_new_window=”on”]linkedin[\/et_pb_social_media_follow_network][\/et_pb_social_media_follow][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”]Michelle Burke is an experienced Non-Executive Chair and Director, and a current member of the Pharmaceutical Benefits Advisory Committee. Michelle is Non-executive Chair of Cell Therapies Pty Ltd, Non-Executive Director for AdAlta Pty Ltd (ASX:1AD), the Olivia Newton-John Cancer Research Institute, and Senseye Australia Pty Ltd. She is also a past Chair of AusBiotech Ltd. Michelle serves as an advisor for early stage research commercialisation, and is also a consultant to health-related companies, governments and academia. Previous executive experience includes more than two decades in commercial director roles with multinational pharmaceutical companies. [\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ module_id=”adam-caplan” _builder_version=”4.27.4″ _module_preset=”default” custom_margin=”||0px||false|false” custom_padding=”||0px||false|false” locked=”off” global_colors_info=”{}”][et_pb_row column_structure=”1_4,3_4″ use_custom_gutter=”on” gutter_width=”2″ _builder_version=”4.27.4″ _module_preset=”default” custom_margin=”0px||0px||true|false” custom_padding=”0px||0px||true|false” global_colors_info=”{}”][et_pb_column type=”1_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_image src=”https:\/\/braintechaustralia.com.au\/2025\/wp-content\/uploads\/2025\/08\/braintech-2025-speakers-adam-caplan-500px.jpg” alt=”Adam Caplan” title_text=”Adam Caplan” _builder_version=”4.27.4″ _module_preset=”default” border_width_all=”5px” border_color_all=”#CCE8E9″ global_colors_info=”{}”][\/et_pb_image][\/et_pb_column][et_pb_column type=”3_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” text_font=”|600|||||||” text_text_color=”#002933″ header_3_font=”|700||on|||||” header_3_text_color=”#DC6B5B” custom_margin=”||0px||false|false” custom_padding=”||0px||false|false” global_colors_info=”{}”]<\/p>\n

Adam Caplan<\/h3>\n

Founder and General Partner, Jumpspace Ventures[\/et_pb_text][et_pb_social_media_follow _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_social_media_follow_network social_network=”linkedin” url=”https:\/\/www.linkedin.com\/in\/adamcaplan” _builder_version=”4.27.4″ _module_preset=”default” background_color=”#DC6B5B” background_enable_color=”on” global_colors_info=”{}” icon_color__hover_enabled=”off|desktop” background__hover_enabled=”on|hover” background_color__hover=”#8ABCBB” background_enable_color__hover=”on” follow_button=”off” url_new_window=”on”]linkedin[\/et_pb_social_media_follow_network][\/et_pb_social_media_follow][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n

Jumspace Ventures is a New York based venture capital firm focused on breakthrough innovations in neuroscience and human-machine interfaces. The firm invests in early-stage companies advancing brain-computer interfaces, neuromodulation and neural diagnostics.<\/p>\n

Adam is also a Co-Founder at Artisan Council, a digital marketing agency, as well as a Co-Founder and Board Member at Facteus, a provider of consumer transaction data to hedge funds.<\/p>\n

Earlier in his career, Adam co-founded ID8 Investments, a diversified venture capital firm, as well as Super Rewards, a monetization solution for social network games which was acquired by Adknowledge in 2009. Before that, he worked as an investment banker with Morgan Stanley for eleven years, focusing on the emerging Internet and new media sectors.<\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ disabled_on=”on|on|on” module_id=”hon-weng-chong” _builder_version=”4.27.4″ _module_preset=”default” custom_margin=”||0px||false|false” custom_padding=”||0px||false|false” disabled=”on” global_colors_info=”{}”][et_pb_row column_structure=”1_4,3_4″ use_custom_gutter=”on” gutter_width=”2″ _builder_version=”4.27.4″ _module_preset=”default” custom_margin=”0px||0px||true|false” custom_padding=”0px||0px||true|false” global_colors_info=”{}”][et_pb_column type=”1_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_image src=”https:\/\/braintechaustralia.com.au\/2025\/wp-content\/uploads\/2025\/06\/braintech-2025-speakers-hon-weng-chong-500px.jpg” alt=”Hon Weng Chong” title_text=”Hon Weng Chong” _builder_version=”4.27.4″ _module_preset=”default” border_width_all=”5px” border_color_all=”#CCE8E9″ global_colors_info=”{}”][\/et_pb_image][\/et_pb_column][et_pb_column type=”3_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” text_font=”|600|||||||” text_text_color=”#002933″ header_3_font=”|700||on|||||” header_3_text_color=”#DC6B5B” custom_margin=”||0px||false|false” custom_padding=”||0px||false|false” global_colors_info=”{}”]<\/p>\n

Hon Weng Chong<\/h3>\n

CEO and Founder, Cortical Labs<\/p>\n

[\/et_pb_text][et_pb_social_media_follow _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_social_media_follow_network social_network=”linkedin” url=”https:\/\/www.linkedin.com\/in\/hochong” _builder_version=”4.27.4″ _module_preset=”default” background_color=”#DC6B5B” background_enable_color=”on” global_colors_info=”{}” icon_color__hover_enabled=”off|desktop” background__hover_enabled=”on|hover” background_color__hover=”#8ABCBB” background_enable_color__hover=”on” follow_button=”off” url_new_window=”on”]linkedin[\/et_pb_social_media_follow_network][\/et_pb_social_media_follow][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”]Hon Weng Chong is the founder and CEO of Cortical Labs, a Deep Technology startup looking to fuse biological material with computing chips resulting in a proto-AGI device. Previously he was the founder and CTO of CliniCloud; a medtech startup that built full-stack connected medical devices that was backed by Tencent and Ping An ventures.<\/p>\n

Hon Weng trained as a medical doctor at The University of Melbourne and was exposed to the world of technology entrepreneurialism during his research year at Johns Hopkins. In addition to being a medical doctor, Hon Weng is a full-stack software engineer and a machine learning enthusiast. Hon Weng is a Forbes 30 under 30 recipient in 2016.[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ module_id=”mark-cook” _builder_version=”4.27.4″ _module_preset=”default” custom_margin=”||0px||false|false” custom_padding=”||0px||false|false” global_colors_info=”{}”][et_pb_row column_structure=”1_4,3_4″ use_custom_gutter=”on” gutter_width=”2″ _builder_version=”4.27.4″ _module_preset=”default” custom_margin=”0px||0px||true|false” custom_padding=”0px||0px||true|false” global_colors_info=”{}”][et_pb_column type=”1_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_image src=”https:\/\/braintechaustralia.com.au\/2025\/wp-content\/uploads\/2025\/07\/braintech-2025-speakers-mark-cook-500px.jpg” alt=”Mark Cook” title_text=”Mark Cook” _builder_version=”4.27.4″ _module_preset=”default” border_width_all=”5px” border_color_all=”#CCE8E9″ global_colors_info=”{}”][\/et_pb_image][\/et_pb_column][et_pb_column type=”3_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” text_font=”|600|||||||” text_text_color=”#002933″ header_3_font=”|700||on|||||” header_3_text_color=”#DC6B5B” custom_margin=”||0px||false|false” custom_padding=”||0px||false|false” global_colors_info=”{}”]<\/p>\n

Professor Mark Cook<\/h3>\n

The Sir John Eccles Chair of Medicine and Director of Clinical Neurosciences, St. Vincent’s Hospital<\/p>\n

[\/et_pb_text][et_pb_social_media_follow _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_social_media_follow_network social_network=”linkedin” url=”https:\/\/www.linkedin.com\/in\/mark-cook-ao-6a616324″ _builder_version=”4.27.4″ _module_preset=”default” background_color=”#DC6B5B” background_enable_color=”on” global_colors_info=”{}” icon_color__hover_enabled=”off|desktop” background__hover_enabled=”on|hover” background_color__hover=”#8ABCBB” background_enable_color__hover=”on” follow_button=”off” url_new_window=”on”]linkedin[\/et_pb_social_media_follow_network][\/et_pb_social_media_follow][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” link_font=”||||on|||#DC6B5B|” link_text_color=”#002933″ global_colors_info=”{}”]<\/p>\n

Mark Cook is Professor of Biomedical Engineering and Sir John Eccles Chair of Medicine, University of Melbourne, and Director of Neurology at St. Vincent\u2019s Hospital Melbourne. He is a neurologist recognised internationally for his expertise in epilepsy management, particularly imaging and surgical planning. In 2023 he was named an Officer in the General Division of the Order of Australia (AO) for distinguished service to neurological medicine and research through contributions to the treatment of epilepsy. He has worked closely with engineers for most of his career, developing novel therapies for epilepsy. His interests have included experimental models of epilepsy and seizure prediction, and he has led 3 first in human clinical studies of epilepsy devices, and is involved in the commercialisation of an implantable seizure detection device – Epiminder<\/a> – that received FDA approval in May 2025.<\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ disabled_on=”off|off|off” module_id=”ruwini-cooray” _builder_version=”4.27.4″ _module_preset=”default” custom_margin=”||0px||false|false” custom_padding=”||0px||false|false” global_colors_info=”{}”][et_pb_row column_structure=”1_4,3_4″ use_custom_gutter=”on” gutter_width=”2″ _builder_version=”4.27.4″ _module_preset=”default” custom_margin=”0px||0px||true|false” custom_padding=”0px||0px||true|false” global_colors_info=”{}”][et_pb_column type=”1_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_image src=”https:\/\/braintechaustralia.com.au\/2025\/wp-content\/uploads\/2025\/10\/braintech-2025-speakers-ruwini-cooray-500px.jpg” alt=”Ruwini Cooray” title_text=”Ruwini Cooray” _builder_version=”4.27.4″ _module_preset=”default” border_width_all=”5px” border_color_all=”#CCE8E9″ global_colors_info=”{}”][\/et_pb_image][\/et_pb_column][et_pb_column type=”3_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” text_font=”|600|||||||” text_text_color=”#002933″ header_3_font=”|700||on|||||” header_3_text_color=”#DC6B5B” custom_margin=”||0px||false|false” custom_padding=”||0px||false|false” global_colors_info=”{}”]<\/p>\n

Ruwini Cooray<\/h3>\n

Founder and Chief Executive Officer, Neurogen<\/p>\n

[\/et_pb_text][et_pb_social_media_follow _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_social_media_follow_network social_network=”linkedin” url=”http:\/\/www.linkedin.com\/in\/ruwini-n-cooray” _builder_version=”4.27.4″ _module_preset=”default” background_color=”#DC6B5B” background_enable_color=”on” global_colors_info=”{}” icon_color__hover_enabled=”off|desktop” background__hover_enabled=”on|hover” background_color__hover=”#8ABCBB” background_enable_color__hover=”on” follow_button=”off” url_new_window=”on”]linkedin[\/et_pb_social_media_follow_network][\/et_pb_social_media_follow][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”]Ruwini Cooray is a Postdoctoral Research Fellow at Deakin University with over fifteen years of research experience in neuroscience, molecular biology, and genetics. Her scientific work is situated at the intersection of neurogenetics and neurophysiology, with a particular emphasis on the molecular and cellular mechanisms underlying intelligence, learning, and memory. Her research further investigates cannabinoid-mediated neuroplasticity and the therapeutic potential of endocannabinoid signalling in neurodegenerative diseases such as Alzheimer\u2019s and Parkinson\u2019s disease. She has published peer-reviewed studies and has been invited to present her work at national and international scientific events.<\/p>\n

Ruwini is the Founder and Chief Executive Officer of Neurogen Global Pty Ltd (Neurogen), a BioTech\/NeuroTech startup developing an advanced biological brain implant designed to repair cortical atrophy: a primary pathological feature responsible for functional decline in neurodegenerative diseases. The implant aims to restore neuronal circuitry and improve cognitive and functional outcomes through a minimally invasive, tissue-based approach.<\/p>\n

She also established Nova Intelligence Network, an interdisciplinary initiative dedicated to advancing the understanding of human intelligence by integrating neuroscience, genetics, and computational modelling. Through her combined academic and translational research, Ruwini seeks to bridge fundamental neurobiology with emerging neurotechnology to develop novel strategies for brain repair and cognitive enhancement.[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ module_id=”rachel-de-las-heras” _builder_version=”4.27.4″ _module_preset=”default” custom_margin=”||0px||false|false” custom_padding=”||0px||false|false” global_colors_info=”{}”][et_pb_row column_structure=”1_4,3_4″ use_custom_gutter=”on” gutter_width=”2″ _builder_version=”4.27.4″ _module_preset=”default” custom_margin=”0px||0px||true|false” custom_padding=”0px||0px||true|false” global_colors_info=”{}”][et_pb_column type=”1_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_image src=”https:\/\/braintechaustralia.com.au\/2025\/wp-content\/uploads\/2025\/07\/braintech-2025-speakers-rachel-de-las-heras-500px.jpg” alt=”Rachel de las Heras” title_text=”Rachel de las Heras” _builder_version=”4.27.4″ _module_preset=”default” border_width_all=”5px” border_color_all=”#CCE8E9″ global_colors_info=”{}”][\/et_pb_image][\/et_pb_column][et_pb_column type=”3_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” text_font=”|600|||||||” text_text_color=”#002933″ header_3_font=”|700||on|||||” header_3_text_color=”#DC6B5B” custom_margin=”||0px||false|false” custom_padding=”||0px||false|false” global_colors_info=”{}”]<\/p>\n

Rachel de las Heras<\/h3>\n

CEO, Ceretas[\/et_pb_text][et_pb_social_media_follow _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_social_media_follow_network social_network=”linkedin” url=”https:\/\/www.linkedin.com\/in\/rachel-de-las-heras” _builder_version=”4.27.4″ _module_preset=”default” background_color=”#DC6B5B” background_enable_color=”on” global_colors_info=”{}” icon_color__hover_enabled=”off|desktop” background__hover_enabled=”on|hover” background_color__hover=”#8ABCBB” background_enable_color__hover=”on” follow_button=”off” url_new_window=”on”]linkedin[\/et_pb_social_media_follow_network][\/et_pb_social_media_follow][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”]Ceretas is building the next- generation portable therapeutic ultrasound platform to non-invasively treat neurodegenerative diseases.<\/p>\n

Rachel was formerly the Ultrasound Product Development Manager at the Queensland Brain Institute (QBI), The University of Queensland. Under her leadership, she has overseen medical device development directed at establishing the safety of therapeutic ultrasound in Alzheimer\u2019s disease through the successful completion of a first-in-human study.<\/p>\n

Rachel has developed diagnostic medical devices whilst at Panbio (now Abbott formerly Alere) and Cellestis (now Qiagen). Most notably co-inventing and developing QuantiFERON Monitor, a diagnostic to improve the clinical management of transplant patients now marketed by Qiagen.<\/p>\n

Rachel has commercialised research discoveries whilst at UniQuest and has also held several commercial and business development roles.<\/p>\n

Since completing her PhD in molecular neuroscience, Rachel has worked in leadership positions across various scientific disciplines including biochemistry, organic chemistry and engineering.[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ disabled_on=”off|off|off” module_id=”colin-denver” _builder_version=”4.27.4″ _module_preset=”default” custom_margin=”||0px||false|false” custom_padding=”||0px||false|false” global_colors_info=”{}”][et_pb_row column_structure=”1_4,3_4″ use_custom_gutter=”on” gutter_width=”2″ _builder_version=”4.27.4″ _module_preset=”default” custom_margin=”0px||0px||true|false” custom_padding=”0px||0px||true|false” global_colors_info=”{}”][et_pb_column type=”1_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_image src=”https:\/\/braintechaustralia.com.au\/2025\/wp-content\/uploads\/2025\/10\/braintech-2025-speakers-colin-denver-500px.jpg” alt=”Colin Denver” title_text=”Colin Denver” _builder_version=”4.27.4″ _module_preset=”default” border_width_all=”5px” border_color_all=”#CCE8E9″ global_colors_info=”{}”][\/et_pb_image][\/et_pb_column][et_pb_column type=”3_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” text_font=”|600|||||||” text_text_color=”#002933″ header_3_font=”|700||on|||||” header_3_text_color=”#DC6B5B” custom_margin=”||0px||false|false” custom_padding=”||0px||false|false” global_colors_info=”{}”]<\/p>\n

Colin Denver<\/h3>\n

CEO, SMarT Minds Dx<\/p>\n

[\/et_pb_text][et_pb_social_media_follow _builder_version=”4.27.4″ _module_preset=”default” locked=”off” global_colors_info=”{}”][et_pb_social_media_follow_network social_network=”linkedin” url=”https:\/\/www.linkedin.com\/in\/colindenver\/” _builder_version=”4.27.4″ _module_preset=”default” background_color=”#DC6B5B” background_enable_color=”on” global_colors_info=”{}” icon_color__hover_enabled=”off|desktop” background__hover_enabled=”on|hover” background_color__hover=”#8ABCBB” background_enable_color__hover=”on” follow_button=”off” url_new_window=”on”]linkedin[\/et_pb_social_media_follow_network][\/et_pb_social_media_follow][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”]A proven and dynamic leader with a strong entrepreneurial spirit, Colin Denver has a distinguished record of accomplishment in establishing and driving long-term sustainable growth within organizations.<\/p>\n

As CEO of SpeeDx, Colin spearheaded the company\u2019s entry into the infectious diseases
\ndiagnostic market raising over $70 million, driving the development and commercialization of
\nmolecular diagnostic products. Under Colin\u2019s leadership, the company launched more than 15
\nnew regulated products and secured strategic partnerships with major diagnostics companies like Labcorp and Cepheid which further propelled the company\u2019s success on the global stage. In addition to scaling operations during pandemic lockdowns, Colin played a key role in navigating complex challenges while maintaining ISO13485 & MDSAP-certified Quality Management Systems.<\/p>\n

In previous roles at Meridian Bioscience and Bioline, Colin led regional offices and built high-
\nperforming teams across Asia-Pacific, growing market share and establishing the groundwork for new product launches in multiple global markets.<\/p>\n

Colin is now leading SMarT Minds Dx, advancing the commercialisation of novel blood-based
\nbiomarkers to enable earlier and more accurate detection of Alzheimer\u2019s Disease pathology.
\nColin holds a Bachelor of Science in Biology from Pepperdine University is actively involved in
\ncommunity service as a Surf Life Saving patroller with Bilgola Surf Life Saving Club, where
\nColin also serves as a Committee member.[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ module_id=”simon-goodrich” _builder_version=”4.27.4″ _module_preset=”default” custom_margin=”||0px||false|false” custom_padding=”||0px||false|false” global_colors_info=”{}”][et_pb_row column_structure=”1_4,3_4″ use_custom_gutter=”on” gutter_width=”2″ _builder_version=”4.27.4″ _module_preset=”default” custom_margin=”0px||0px||true|false” custom_padding=”0px||0px||true|false” global_colors_info=”{}”][et_pb_column type=”1_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_image src=”https:\/\/braintechaustralia.com.au\/2025\/wp-content\/uploads\/2025\/10\/braintech-2025-speakers-simon-goodrich-500px.jpg” alt=”Simon Goodrich” title_text=”Simon Goodrich” _builder_version=”4.27.4″ _module_preset=”default” border_width_all=”5px” border_color_all=”#CCE8E9″ global_colors_info=”{}”][\/et_pb_image][\/et_pb_column][et_pb_column type=”3_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” text_font=”|600|||||||” text_text_color=”#002933″ header_3_font=”|700||on|||||” header_3_text_color=”#DC6B5B” custom_margin=”||0px||false|false” custom_padding=”||0px||false|false” global_colors_info=”{}”]<\/p>\n

Simon Goodrich<\/h3>\n

Co-founder, Portable<\/p>\n

[\/et_pb_text][et_pb_social_media_follow _builder_version=”4.27.4″ _module_preset=”default” locked=”off” global_colors_info=”{}”][et_pb_social_media_follow_network social_network=”linkedin” url=”https:\/\/www.linkedin.com\/in\/simongoodrich\/” _builder_version=”4.27.4″ _module_preset=”default” background_color=”#DC6B5B” background_enable_color=”on” global_colors_info=”{}” icon_color__hover_enabled=”off|desktop” background__hover_enabled=”on|hover” background_color__hover=”#8ABCBB” background_enable_color__hover=”on” follow_button=”off” url_new_window=”on”]linkedin[\/et_pb_social_media_follow_network][\/et_pb_social_media_follow][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n

Simon Goodrich is a design and innovation leader with over 20 years of experience at the intersection of human-centred design, digital transformation, and social impact. As Co-founder of Portable, Simon has played a pivotal role in shaping the company\u2019s design practice\u2014bringing together service design, technology, and policy to reimagine how the justice system, government, and health services operate.<\/p>\n

Simon\u2019s design leadership has seen Portable become an internationally recognised agency for access to justice innovation, responsible for developing products like amica<\/em>, a tool that helps people separate without lawyers, and Hear Me Out<\/em>, one of the world\u2019s first AI-powered legal self-help platforms. He is passionate about designing for inclusion, and Portable\u2019s commitment to trauma-informed, ethically grounded design.<\/p>\n

Simon\u2019s approach is grounded in co-design and systems thinking, consistently advocating for design as a strategic lever in tackling complex policy challenges. Through partnerships with institutions such as Webby Awards, Stanford Legal Design Lab, and the National Center for State Courts, Simon has positioned Portable as a global contributor to justice reform and civic innovation.<\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ module_id=”brett-kagan” _builder_version=”4.27.4″ _module_preset=”default” custom_margin=”||0px||false|false” custom_padding=”||0px||false|false” global_colors_info=”{}”][et_pb_row column_structure=”1_4,3_4″ use_custom_gutter=”on” gutter_width=”2″ _builder_version=”4.27.4″ _module_preset=”default” custom_margin=”0px||0px||true|false” custom_padding=”0px||0px||true|false” global_colors_info=”{}”][et_pb_column type=”1_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_image src=”https:\/\/braintechaustralia.com.au\/2025\/wp-content\/uploads\/2025\/09\/braintech-2025-speakers-brett-kagan-500px.jpg” alt=”Brett Kagan” title_text=”Brett Kagan” _builder_version=”4.27.4″ _module_preset=”default” border_width_all=”5px” border_color_all=”#CCE8E9″ global_colors_info=”{}”][\/et_pb_image][\/et_pb_column][et_pb_column type=”3_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” text_font=”|600|||||||” text_text_color=”#002933″ header_3_font=”|700||on|||||” header_3_text_color=”#DC6B5B” custom_margin=”||0px||false|false” custom_padding=”||0px||false|false” global_colors_info=”{}”]<\/p>\n

Dr Brett J. Kagan<\/h3>\n

Chief Scientific Officer & Chief Operations Officer, Cortical Labs<\/p>\n

[\/et_pb_text][et_pb_social_media_follow _builder_version=”4.27.4″ _module_preset=”default” locked=”off” global_colors_info=”{}”][et_pb_social_media_follow_network social_network=”linkedin” url=”https:\/\/www.linkedin.com\/in\/brett-kagan-6ba996146″ _builder_version=”4.27.4″ _module_preset=”default” background_color=”#DC6B5B” background_enable_color=”on” global_colors_info=”{}” icon_color__hover_enabled=”off|desktop” background__hover_enabled=”on|hover” background_color__hover=”#8ABCBB” background_enable_color__hover=”on” follow_button=”off” url_new_window=”on”]linkedin[\/et_pb_social_media_follow_network][\/et_pb_social_media_follow][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”]Dr Brett J. Kagan\u2019s work as a pioneering scientist building intelligent systems from neural cultures via synthetic biology has earned both national and international recognition both in the mainstream and scientific communities. As the only scientist to be jointly awarded both the Mark Rowe award and the Paxinos Watson award from the Australasian Neuroscience Society, Dr Kagan\u2019s scientific publications have generated worldwide recognition for establishing and developing the fields of Synthetic Biological
\nIntelligence, Organoid Intelligence, and Bioengineered Intelligence. <\/p>\n

Dr Kagan has a PhD in neuroscience focusing on stem cell therapy and completed post-doctoral work in bioinformatics and regenerative medicine. <\/p>\n

Cortical Labs is a multidisciplinary deep-tech startup looking at integrating hardware, software, and synthetic biology approaches to pioneer harnessing intelligence from brain cells on a chip.[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ module_id=”philippa-karoly” _builder_version=”4.27.4″ _module_preset=”default” custom_margin=”||0px||false|false” custom_padding=”||0px||false|false” global_colors_info=”{}”][et_pb_row column_structure=”1_4,3_4″ use_custom_gutter=”on” gutter_width=”2″ _builder_version=”4.27.4″ _module_preset=”default” custom_margin=”0px||0px||true|false” custom_padding=”0px||0px||true|false” global_colors_info=”{}”][et_pb_column type=”1_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_image src=”https:\/\/braintechaustralia.com.au\/2025\/wp-content\/uploads\/2025\/09\/braintech-2025-speakers-philippa-karoly-500px.jpg” alt=”Philippa Karoly” title_text=”Philippa Karoly” _builder_version=”4.27.4″ _module_preset=”default” border_width_all=”5px” border_color_all=”#CCE8E9″ global_colors_info=”{}”][\/et_pb_image][\/et_pb_column][et_pb_column type=”3_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” text_font=”|600|||||||” text_text_color=”#002933″ header_3_font=”|700||on|||||” header_3_text_color=”#DC6B5B” custom_margin=”||0px||false|false” custom_padding=”||0px||false|false” global_colors_info=”{}”]<\/p>\n

Philippa Jane Karoly<\/h3>\n

Senior Lecturer, Department of Biomedical Engineering, The University of Melbourne<\/p>\n

[\/et_pb_text][et_pb_social_media_follow _builder_version=”4.27.4″ _module_preset=”default” locked=”off” global_colors_info=”{}”][et_pb_social_media_follow_network social_network=”linkedin” url=”https:\/\/www.linkedin.com\/in\/pip-karoly-7a33b015b” _builder_version=”4.27.4″ _module_preset=”default” background_color=”#DC6B5B” background_enable_color=”on” global_colors_info=”{}” icon_color__hover_enabled=”off|desktop” background__hover_enabled=”on|hover” background_color__hover=”#8ABCBB” background_enable_color__hover=”on” follow_button=”off” url_new_window=”on”]linkedin[\/et_pb_social_media_follow_network][\/et_pb_social_media_follow][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”]Philippa (Pip) Karoly is focused on developing translational clinical software and digital health tools to understand and manage neurological diseases. Dr. Karoly was awarded the 2022 Prime Minister’s Prize for New Innovators for her breakthrough scientific research into seizure cycles and the development of a mobile app for people with epilepsy to track their likelihood of having a seizure across hourly, daily or monthly timescales. Pip’s research group, the Rhythms in Physiology Lab (RiPL) are unravelling mechanisms of multiday cycles in the brain, heart and body, to inform personalised disease management and optimise health, wellbeing, and performance. Using circular statistics and accessible (mobile\/wearable) software, long-term data from brain recordings, physiological and genetic samples, environmental, and behavioural factors can be combined to understand these slow rhythms. Dr Karoly collaborates with industry partners to develop innovative, personalised approaches to monitor cycles of disease risk.[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ disabled_on=”on|on|on” module_id=”trish-lavery” _builder_version=”4.27.4″ _module_preset=”default” custom_margin=”||0px||false|false” custom_padding=”||0px||false|false” disabled=”on” global_colors_info=”{}”][et_pb_row column_structure=”1_4,3_4″ use_custom_gutter=”on” gutter_width=”2″ _builder_version=”4.27.4″ _module_preset=”default” custom_margin=”0px||0px||true|false” custom_padding=”0px||0px||true|false” global_colors_info=”{}”][et_pb_column type=”1_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_image src=”https:\/\/braintechaustralia.com.au\/2025\/wp-content\/uploads\/2025\/07\/braintech-2025-speakers-trish-lavery-500px.jpg” alt=”Trish Lavery” title_text=”Trish Lavery” _builder_version=”4.27.4″ _module_preset=”default” border_width_all=”5px” border_color_all=”#CCE8E9″ global_colors_info=”{}”][\/et_pb_image][\/et_pb_column][et_pb_column type=”3_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” text_font=”|600|||||||” text_text_color=”#002933″ header_3_font=”|700||on|||||” header_3_text_color=”#DC6B5B” custom_margin=”||0px||false|false” custom_padding=”||0px||false|false” global_colors_info=”{}”]<\/p>\n

Trish Lavery<\/h3>\n

Visiting Fellow, School of Cybernetics, Australian National University[\/et_pb_text][et_pb_social_media_follow _builder_version=”4.27.4″ _module_preset=”default” locked=”off” global_colors_info=”{}”][et_pb_social_media_follow_network social_network=”linkedin” url=”https:\/\/www.linkedin.com\/in\/trishlavery” _builder_version=”4.27.4″ _module_preset=”default” background_color=”#DC6B5B” background_enable_color=”on” global_colors_info=”{}” icon_color__hover_enabled=”off|desktop” background__hover_enabled=”on|hover” background_color__hover=”#8ABCBB” background_enable_color__hover=”on” follow_button=”off” url_new_window=”on”]linkedin[\/et_pb_social_media_follow_network][\/et_pb_social_media_follow][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”]Trish Lavery is an academic and policy expert working at the Australian National University and currently leading a foresight project on the social and geopolitical aspects of emerging climate cooling technologies. Her work places human behaviour at the centre of strategy, futures, and strategic foresight. Trish has worked as part of the Policy Projects and Taskforce Office at the Department of the Prime Minister and Cabinet and as Strategic Foresight Counsellor for the Office of the Secretary-General, OECD. Prior to her role at the OECD, Trish worked for 10 years in the Australian Government’s environment directorate as a behavioural insights practitioner.[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ disabled_on=”on|on|on” module_id=”rachel-levin” _builder_version=”4.27.4″ _module_preset=”default” custom_margin=”||0px||false|false” custom_padding=”||0px||false|false” disabled=”on” locked=”off” global_colors_info=”{}”][et_pb_row column_structure=”1_4,3_4″ use_custom_gutter=”on” gutter_width=”2″ _builder_version=”4.27.4″ _module_preset=”default” custom_margin=”0px||0px||true|false” custom_padding=”0px||0px||true|false” global_colors_info=”{}”][et_pb_column type=”1_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_image src=”https:\/\/braintechaustralia.com.au\/2025\/wp-content\/uploads\/2025\/08\/braintech-2025-speakers-rachel-levin-500px.jpg” alt=”Rachel Levin” title_text=”Rachel Levin” _builder_version=”4.27.4″ _module_preset=”default” border_width_all=”5px” border_color_all=”#CCE8E9″ global_colors_info=”{}”][\/et_pb_image][\/et_pb_column][et_pb_column type=”3_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” text_font=”|600|||||||” text_text_color=”#002933″ header_3_font=”|700||on|||||” header_3_text_color=”#DC6B5B” custom_margin=”||0px||false|false” custom_padding=”||0px||false|false” global_colors_info=”{}”]<\/p>\n

Rachel Levin<\/h3>\n

Investment Director, National Reconstruction Fund Corporation<\/p>\n

[\/et_pb_text][et_pb_social_media_follow _builder_version=”4.27.4″ _module_preset=”default” locked=”off” global_colors_info=”{}”][et_pb_social_media_follow_network social_network=”linkedin” url=”https:\/\/www.linkedin.com\/in\/rachel-levin-7084b845″ _builder_version=”4.27.4″ _module_preset=”default” background_color=”#DC6B5B” background_enable_color=”on” global_colors_info=”{}” icon_color__hover_enabled=”off|desktop” background__hover_enabled=”on|hover” background_color__hover=”#8ABCBB” background_enable_color__hover=”on” follow_button=”off” url_new_window=”on”]linkedin[\/et_pb_social_media_follow_network][\/et_pb_social_media_follow][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”]The National Reconstruction Fund is a $15 billion fund established by the Australian government to help grow the economy and create jobs. The fund operates as an independent financier, separate from the government, and will invest in priority areas of the economy, including medical science, resources, defence capability, transport, and renewable energy. <\/p>\n

Rachel is a biotech and medtech investor with experience across research (MSc, PhD, industry), startups, and big pharma.[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ disabled_on=”on|on|on” module_id=”geoffrey-mackellar” _builder_version=”4.27.4″ _module_preset=”default” custom_margin=”||0px||false|false” custom_padding=”||0px||false|false” disabled=”on” global_colors_info=”{}”][et_pb_row column_structure=”1_4,3_4″ use_custom_gutter=”on” gutter_width=”2″ _builder_version=”4.27.4″ _module_preset=”default” custom_margin=”0px||0px||true|false” custom_padding=”0px||0px||true|false” global_colors_info=”{}”][et_pb_column type=”1_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_image src=”https:\/\/braintechaustralia.com.au\/2025\/wp-content\/uploads\/2025\/06\/braintech-2025-speakers-geoffrey-mackellar-500px.jpg” alt=”Geoffrey Mackellar” title_text=”Geoffrey Mackellar” _builder_version=”4.27.4″ _module_preset=”default” border_width_all=”5px” border_color_all=”#CCE8E9″ global_colors_info=”{}”][\/et_pb_image][\/et_pb_column][et_pb_column type=”3_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” text_font=”|600|||||||” text_text_color=”#002933″ header_3_font=”|700||on|||||” header_3_text_color=”#DC6B5B” custom_margin=”||0px||false|false” custom_padding=”||0px||false|false” global_colors_info=”{}”]<\/p>\n

Dr Geoffrey Mackellar<\/h3>\n

CTO, EMOTIV<\/p>\n

[\/et_pb_text][et_pb_social_media_follow _builder_version=”4.27.4″ _module_preset=”default” locked=”off” global_colors_info=”{}”][et_pb_social_media_follow_network social_network=”linkedin” url=”https:\/\/www.linkedin.com\/in\/geoffmackellar” _builder_version=”4.27.4″ _module_preset=”default” background_color=”#DC6B5B” background_enable_color=”on” global_colors_info=”{}” icon_color__hover_enabled=”off|desktop” background__hover_enabled=”on|hover” background_color__hover=”#8ABCBB” background_enable_color__hover=”on” follow_button=”off” url_new_window=”on”]linkedin[\/et_pb_social_media_follow_network][\/et_pb_social_media_follow][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”]Dr. Geoff Mackellar is based in Sydney, Australia, where he heads EMOTIV’s R&D hub located at the Macquarie University Incubator. His leadership has been instrumental in EMOTIV’s mission to democratize brain research and make neurotechnology accessible to a global community of researchers and developers. <\/p>\n

Geoff obtained his PhD in Laser Physics from Macquarie University between 1979 and 1985. Prior to that, they obtained a BSc(Hons1) in Physics(Hons), Mathematics, and Computing from the University of New England (AU) between 1975 and 1978.[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ module_id=”helen-macpherson” _builder_version=”4.27.4″ _module_preset=”default” custom_margin=”||0px||false|false” custom_padding=”||0px||false|false” global_colors_info=”{}”][et_pb_row column_structure=”1_4,3_4″ use_custom_gutter=”on” gutter_width=”2″ _builder_version=”4.27.4″ _module_preset=”default” custom_margin=”0px||0px||true|false” custom_padding=”0px||0px||true|false” global_colors_info=”{}”][et_pb_column type=”1_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_image src=”https:\/\/braintechaustralia.com.au\/2025\/wp-content\/uploads\/2025\/06\/braintech-2025-speakers-helen-macpherson-500px.jpg” alt=”Helen Macpherson” title_text=”Helen Macpherson” _builder_version=”4.27.4″ _module_preset=”default” border_width_all=”5px” border_color_all=”#CCE8E9″ global_colors_info=”{}”][\/et_pb_image][\/et_pb_column][et_pb_column type=”3_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” text_font=”|600|||||||” text_text_color=”#002933″ header_3_font=”|700||on|||||” header_3_text_color=”#DC6B5B” custom_margin=”||0px||false|false” custom_padding=”||0px||false|false” global_colors_info=”{}”]<\/p>\n

Dr Helen Macpherson<\/h3>\n

Senior Research Fellow, Institute for Physical Activity and Nutrition (IPAN), Deakin University<\/p>\n

[\/et_pb_text][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n

Dr Helen Macpherson is leading a program of dementia prevention research at Deakin University. Her work encompasses the identification and modification of health and lifestyle determinants of dementia risk, assessment of neurocognitive ageing and early detection of dementia and cognitive decline.<\/p>\n

Dr Macpherson has received $4 million funding to support this research. She has expertise in the design and conduct of randomised controlled trials. Dr Macpherson also has experience working with large population-based data sets. She is currently supervising several PhD students using various neuroimaging techniques to study age-related changes in cognition. Drawing on her background in cognitive neuroscience and psychology, Dr Macpherson\u2019s work is contributing to the important knowledge that dementia risk can be reduced by targeting health behaviours.<\/p>\n

Dr Macpherson contributed to the development of Dementia Australia\u2019s BrainTrack<\/em> app, a pioneering tool designed for self-monitoring cognition, which has already reached 150,000 downloads.<\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ module_id=”tim-mahoney” _builder_version=”4.27.4″ _module_preset=”default” custom_margin=”||0px||false|false” custom_padding=”||0px||false|false” global_colors_info=”{}”][et_pb_row column_structure=”1_4,3_4″ use_custom_gutter=”on” gutter_width=”2″ _builder_version=”4.27.4″ _module_preset=”default” custom_margin=”0px||0px||true|false” custom_padding=”0px||0px||true|false” global_colors_info=”{}”][et_pb_column type=”1_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_image src=”https:\/\/braintechaustralia.com.au\/2025\/wp-content\/uploads\/2025\/09\/braintech-2025-speakers-tim-mahoney-500px.jpg” alt=”Tim Mahoney” title_text=”Tim Mahoney” _builder_version=”4.27.4″ _module_preset=”default” border_width_all=”5px” border_color_all=”#CCE8E9″ global_colors_info=”{}”][\/et_pb_image][\/et_pb_column][et_pb_column type=”3_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” text_font=”|600|||||||” text_text_color=”#002933″ header_3_font=”|700||on|||||” header_3_text_color=”#DC6B5B” custom_margin=”||0px||false|false” custom_padding=”||0px||false|false” global_colors_info=”{}”]<\/p>\n

Tim Mahoney<\/h3>\n

CEO, Fluent<\/p>\n

[\/et_pb_text][et_pb_social_media_follow _builder_version=”4.27.4″ _module_preset=”default” locked=”off” global_colors_info=”{}”][et_pb_social_media_follow_network social_network=”linkedin” url=”https:\/\/www.linkedin.com\/in\/tim-mahoney-4709a04b\/” _builder_version=”4.27.4″ _module_preset=”default” background_color=”#DC6B5B” background_enable_color=”on” global_colors_info=”{}” icon_color__hover_enabled=”off|desktop” background__hover_enabled=”on|hover” background_color__hover=”#8ABCBB” background_enable_color__hover=”on” follow_button=”off” url_new_window=”on”]linkedin[\/et_pb_social_media_follow_network][\/et_pb_social_media_follow][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”]Tim Mahoney has long been driven to close the gap between people and technology. After completing a PhD in brain-computer interfaces, he co-founded Fluent to build what was missing: a truly scalable BCI solution. His team is now developing a groundbreaking platform that allows people to control technology directly with their intent.[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ module_id=”andrew-maxwell” _builder_version=”4.27.4″ _module_preset=”default” custom_margin=”||0px||false|false” custom_padding=”||0px||false|false” global_colors_info=”{}”][et_pb_row column_structure=”1_4,3_4″ use_custom_gutter=”on” gutter_width=”2″ _builder_version=”4.27.4″ _module_preset=”default” custom_margin=”0px||0px||true|false” custom_padding=”0px||0px||true|false” global_colors_info=”{}”][et_pb_column type=”1_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_image src=”https:\/\/braintechaustralia.com.au\/2025\/wp-content\/uploads\/2025\/06\/braintech-2025-speakers-andrew-maxwell-500px.jpg” alt=”Andrew Maxwell” title_text=”Andrew Maxwell” _builder_version=”4.27.4″ _module_preset=”default” border_width_all=”5px” border_color_all=”#CCE8E9″ global_colors_info=”{}”][\/et_pb_image][\/et_pb_column][et_pb_column type=”3_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” text_font=”|600|||||||” text_text_color=”#002933″ header_3_font=”|700||on|||||” header_3_text_color=”#DC6B5B” custom_margin=”||0px||false|false” custom_padding=”||0px||false|false” global_colors_info=”{}”]<\/p>\n

Andrew Maxwell<\/h3>\n

Chairman, Wavewise Analytics (Cyban)[\/et_pb_text][et_pb_social_media_follow _builder_version=”4.27.4″ _module_preset=”default” locked=”off” global_colors_info=”{}”][et_pb_social_media_follow_network social_network=”linkedin” url=”https:\/\/www.linkedin.com\/in\/andrew-maxwell-7860771″ _builder_version=”4.27.4″ _module_preset=”default” background_color=”#DC6B5B” background_enable_color=”on” global_colors_info=”{}” icon_color__hover_enabled=”off|desktop” background__hover_enabled=”on|hover” background_color__hover=”#8ABCBB” background_enable_color__hover=”on” follow_button=”off” url_new_window=”on”]linkedin[\/et_pb_social_media_follow_network][\/et_pb_social_media_follow][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”]Andrew is MD of Chatsworth Associates, working with innovators, and entrepreneurs to plan equity raisings, corporate transactions, and international business development programs. Andrew is currently the Chairman of Wavewise Analytics (formerly Cyban), which has received funding from several notable funds, including Breakthrough Victoria. Wavewise has developed a next generation brain pulse monitor that advances the treatment of brain injuries by delivering reliable information continuously. From 2021 \u2013 Feb 2024, Andrew was Investment Committee Chair and Venture Partner for Significant Early Venture Capital. As CEO of ESCOR Private Equity (a Smorgon Family Company), Andrew established and managed a $40m investment fund making investments in the IT, Internet, Biotech, Healthcare, Alternative Energy and Manufacturing technology sectors.[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ module_id=”colette-mckay” _builder_version=”4.27.4″ _module_preset=”default” custom_margin=”||0px||false|false” custom_padding=”||0px||false|false” global_colors_info=”{}”][et_pb_row column_structure=”1_4,3_4″ use_custom_gutter=”on” gutter_width=”2″ _builder_version=”4.27.4″ _module_preset=”default” custom_margin=”0px||0px||true|false” custom_padding=”0px||0px||true|false” global_colors_info=”{}”][et_pb_column type=”1_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_image src=”https:\/\/braintechaustralia.com.au\/2025\/wp-content\/uploads\/2025\/10\/braintech-2025-speakers-colette-mckay-500px.jpg” alt=”Colette McKay” title_text=”Colette McKay” _builder_version=”4.27.4″ _module_preset=”default” border_width_all=”5px” border_color_all=”#CCE8E9″ global_colors_info=”{}”][\/et_pb_image][\/et_pb_column][et_pb_column type=”3_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” text_font=”|600|||||||” text_text_color=”#002933″ header_3_font=”|700||on|||||” header_3_text_color=”#DC6B5B” custom_margin=”||0px||false|false” custom_padding=”||0px||false|false” global_colors_info=”{}”]<\/p>\n

Professor Colette McKay<\/h3>\n

Founder, EarGenie\u00ae<\/p>\n

[\/et_pb_text][et_pb_social_media_follow _builder_version=”4.27.4″ _module_preset=”default” locked=”off” global_colors_info=”{}”][et_pb_social_media_follow_network social_network=”linkedin” url=”https:\/\/www.linkedin.com\/in\/colette-mckay-507098149\/” _builder_version=”4.27.4″ _module_preset=”default” background_color=”#DC6B5B” background_enable_color=”on” global_colors_info=”{}” icon_color__hover_enabled=”off|desktop” background__hover_enabled=”on|hover” background_color__hover=”#8ABCBB” background_enable_color__hover=”on” follow_button=”off” url_new_window=”on”]linkedin[\/et_pb_social_media_follow_network][\/et_pb_social_media_follow][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”]Professor Colette McKay leads translational hearing research at the Bionics Institute of Australia and holds honorary appointments with the University of Melbourne\u2019s Department of Medical Bionics and Department of Otolaryngology. She earned a PhD in Physics (1979) and a Diploma in Audiology (1980), and played a pivotal role in the early development of the cochlear implant, earning two prestigious principal research fellowships.<\/p>\n

In 2005, Colette became Chair of Hearing Science at Aston University (UK), where she established a new hearing research program and created the UK\u2019s first undergraduate audiology course. From 2007 to 2013 she led the Audiology and Deafness Research Group at the University of Manchester, where she remains an Honorary Professor. Returning to Australia in 2013 as a veski Senior Innovation Fellow, she now focuses on objective cochlear-implant programming for infants, advancing functional near-infrared spectroscopy (fNIRS) as a tool to study cross-modal plasticity, and applying signal-processing techniques to next-generation deep-brain stimulation devices.<\/p>\n

Colette is also the scientific founder of EarGenie\u00ae, an infant hearing-assessment system commercialised in 2025. Over more than a decade, her multidisciplinary team at the Bionics Institute \u2013 together with co-founders Julia Wunderlich, Gautam Balasubramanian and Darren Mao \u2013 developed the fNIRS-based technology to enable earlier, more accurate intervention for babies with hearing loss and language delay.[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ module_id=”james-mcloughlin” _builder_version=”4.27.4″ _module_preset=”default” custom_margin=”||0px||false|false” custom_padding=”||0px||false|false” global_colors_info=”{}”][et_pb_row column_structure=”1_4,3_4″ use_custom_gutter=”on” gutter_width=”2″ _builder_version=”4.27.4″ _module_preset=”default” custom_margin=”0px||0px||true|false” custom_padding=”0px||0px||true|false” global_colors_info=”{}”][et_pb_column type=”1_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_image src=”https:\/\/braintechaustralia.com.au\/2025\/wp-content\/uploads\/2025\/10\/braintech-2025-speakers-james-mcloughlin-500px.jpg” alt=”James McLoughlin” title_text=”James McLoughlin” _builder_version=”4.27.4″ _module_preset=”default” border_width_all=”5px” border_color_all=”#CCE8E9″ global_colors_info=”{}”][\/et_pb_image][\/et_pb_column][et_pb_column type=”3_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” text_font=”|600|||||||” text_text_color=”#002933″ header_3_font=”|700||on|||||” header_3_text_color=”#DC6B5B” custom_margin=”||0px||false|false” custom_padding=”||0px||false|false” global_colors_info=”{}”]<\/p>\n

Associate Professor James McLoughlin<\/h3>\n

Co-founder and Chief Academic Officer, Your Brain Health<\/p>\n

[\/et_pb_text][et_pb_social_media_follow _builder_version=”4.27.4″ _module_preset=”default” locked=”off” global_colors_info=”{}”][et_pb_social_media_follow_network social_network=”linkedin” url=”https:\/\/www.linkedin.com\/in\/assoc-prof-james-mcloughlin-95a16183\/” _builder_version=”4.27.4″ _module_preset=”default” background_color=”#DC6B5B” background_enable_color=”on” global_colors_info=”{}” icon_color__hover_enabled=”off|desktop” background__hover_enabled=”on|hover” background_color__hover=”#8ABCBB” background_enable_color__hover=”on” follow_button=”off” url_new_window=”on”]linkedin[\/et_pb_social_media_follow_network][\/et_pb_social_media_follow][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”]James McLoughlin is co-founder and Chief Academic Officer at Your Brain Health and Director of Advanced Neuro Rehab clinics in South Australia. James has degrees in both Physiotherapy (UniSA) and Clinical Neuroscience (University College London), a PhD (UNSW), plus over 25 years of clinical experience in neurological and vestibular rehabilitation. James has created post-graduate degree programs at Flinders University and extensive professional development training in the areas of motor control, neurological and vestibular rehabilitation. James loves to blend the knowledge and skills in the areas of neurology, musculoskeletal and sports to improve brain health by empowering people through education, clinical skills and technology.[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ module_id=”andrew-morokoff” _builder_version=”4.27.4″ _module_preset=”default” custom_margin=”||0px||false|false” custom_padding=”||0px||false|false” global_colors_info=”{}”][et_pb_row column_structure=”1_4,3_4″ use_custom_gutter=”on” gutter_width=”2″ _builder_version=”4.27.4″ _module_preset=”default” custom_margin=”0px||0px||true|false” custom_padding=”0px||0px||true|false” global_colors_info=”{}”][et_pb_column type=”1_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_image src=”https:\/\/braintechaustralia.com.au\/2025\/wp-content\/uploads\/2025\/09\/braintech-2025-speakers-andrew-morokoff-500px.jpg” alt=”Andrew Morokoff” title_text=”Andrew Morokoff” _builder_version=”4.27.4″ _module_preset=”default” border_width_all=”5px” border_color_all=”#CCE8E9″ global_colors_info=”{}”][\/et_pb_image][\/et_pb_column][et_pb_column type=”3_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” text_font=”|600|||||||” text_text_color=”#002933″ header_3_font=”|700||on|||||” header_3_text_color=”#DC6B5B” custom_margin=”||0px||false|false” custom_padding=”||0px||false|false” global_colors_info=”{}”]<\/p>\n

Andrew Morokoff<\/h3>\n

Neurosurgeon and Associate Professor, The University of Melbourne<\/p>\n

[\/et_pb_text][et_pb_social_media_follow _builder_version=”4.27.4″ _module_preset=”default” locked=”off” global_colors_info=”{}”][et_pb_social_media_follow_network social_network=”linkedin” url=”https:\/\/www.linkedin.com\/in\/andrew-morokoff-37215521\/” _builder_version=”4.27.4″ _module_preset=”default” background_color=”#DC6B5B” background_enable_color=”on” global_colors_info=”{}” icon_color__hover_enabled=”off|desktop” background__hover_enabled=”on|hover” background_color__hover=”#8ABCBB” background_enable_color__hover=”on” follow_button=”off” url_new_window=”on”]linkedin[\/et_pb_social_media_follow_network][\/et_pb_social_media_follow][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”]Associate Professor Morokoff is an academic neurosurgeon at the Royal Melbourne Hospital,
\nUniversity of Melbourne and the Brain Cancer Centre Australia. He trained in Melbourne and
\nhis PhD is in the biology of glioma. He completed a neuro-oncology fellowship in 2006-2007
\nat Harvard University, Boston and Necker Hospital in Paris. His clinical interests are brain
\ntumour, acoustic neuromas, skull base surgery, epilepsy and his research focuses on liquid
\nbiopsies for brain cancer, brain tumour associated epilepsy and novel brain-computer
\ninterfaces. He was the neurosurgeon for the first-in-human clinical trials for NeuroVista,
\nSynchron and Epiminder and is an advisor to a number of innovative brain tech startups.[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ disabled_on=”on|on|on” module_id=”nicholas-opie” _builder_version=”4.27.4″ _module_preset=”default” custom_margin=”||0px||false|false” custom_padding=”||0px||false|false” disabled=”on” global_colors_info=”{}”][et_pb_row column_structure=”1_4,3_4″ use_custom_gutter=”on” gutter_width=”2″ _builder_version=”4.27.4″ _module_preset=”default” custom_margin=”0px||0px||true|false” custom_padding=”0px||0px||true|false” global_colors_info=”{}”][et_pb_column type=”1_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_image src=”https:\/\/braintechaustralia.com.au\/2025\/wp-content\/uploads\/2025\/08\/braintech-2025-speakers-nicholas-opie-500px.jpg” alt=”Nicholas Opie” title_text=”Nicholas Opie” _builder_version=”4.27.4″ _module_preset=”default” border_width_all=”5px” border_color_all=”#CCE8E9″ global_colors_info=”{}”][\/et_pb_image][\/et_pb_column][et_pb_column type=”3_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” text_font=”|600|||||||” text_text_color=”#002933″ header_3_font=”|700||on|||||” header_3_text_color=”#DC6B5B” custom_margin=”||0px||false|false” custom_padding=”||0px||false|false” global_colors_info=”{}”]<\/p>\n

Professor Nicholas Opie<\/h3>\n

CEO, Ultra Bionics and Founding Director, Synchron<\/p>\n

[\/et_pb_text][et_pb_social_media_follow _builder_version=”4.27.4″ _module_preset=”default” locked=”off” global_colors_info=”{}”][et_pb_social_media_follow_network social_network=”linkedin” url=”https:\/\/www.linkedin.com\/in\/nicholas-opie-4603289a\/” _builder_version=”4.27.4″ _module_preset=”default” background_color=”#DC6B5B” background_enable_color=”on” global_colors_info=”{}” icon_color__hover_enabled=”off|desktop” background__hover_enabled=”on|hover” background_color__hover=”#8ABCBB” background_enable_color__hover=”on” follow_button=”off” url_new_window=”on”]linkedin[\/et_pb_social_media_follow_network][\/et_pb_social_media_follow][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”]Professor Nicholas Opie is a global expert in neural interfaces, and endovascular bionics pioneer.<\/p>\n

He designed and developed the world’s first endovascular brain computer interface that can be implanted without invasive brain surgery. His creation, the Stentrode, is aimed at restoring communication, mobility and independence to people with paralysis. He is currently working to develop new neurotechnology to treat other neurological conditions including Epilepsy, depression and Parkinson’s.<\/p>\n

Professor Opie earned his undergraduate degrees in Electrical and Computer Systems Engineering (Hons) and Science at Monash University, his PhD in retinal neuroprostheses at the University of Melbourne and his MBA from Melbourne Business School. He is a Professor, NHMRC Investigator Fellow and Head of the Vascular Bionics Laboratory within the Department of Medicine at the University of Melbourne where he has been awarded more than $30M in research funding to translate his technology from concept to clinic. He is also a Founding Director of Synchron Australia and Synchron Inc, raising more than $200M to commercialise the Stentrode System.<\/p>\n

Professor Opie has published more than 70 peer-reviewed publications, including in Nature Biomedical Engineering and Nature Biotechnology, has presented his work at over 200 local and international conferences and is an inventor of over 110 patents. He has received numerous awards for his inventions, including Times Top 100 inventions in 2022.[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ disabled_on=”on|on|on” module_id=”brooke-parsons” _builder_version=”4.27.4″ _module_preset=”default” custom_margin=”||0px||false|false” custom_padding=”||0px||false|false” disabled=”on” global_colors_info=”{}”][et_pb_row column_structure=”1_4,3_4″ use_custom_gutter=”on” gutter_width=”2″ _builder_version=”4.27.4″ _module_preset=”default” custom_margin=”0px||0px||true|false” custom_padding=”0px||0px||true|false” global_colors_info=”{}”][et_pb_column type=”1_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_image src=”https:\/\/braintechaustralia.com.au\/2025\/wp-content\/uploads\/2025\/09\/braintech-2025-speakers-brooke-parsons-500px.jpg” alt=”Brooke Parsons” title_text=”Brooke Parsons” _builder_version=”4.27.4″ _module_preset=”default” border_width_all=”5px” border_color_all=”#CCE8E9″ global_colors_info=”{}”][\/et_pb_image][\/et_pb_column][et_pb_column type=”3_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” text_font=”|600|||||||” text_text_color=”#002933″ header_3_font=”|700||on|||||” header_3_text_color=”#DC6B5B” custom_margin=”||0px||false|false” custom_padding=”||0px||false|false” global_colors_info=”{}”]<\/p>\n

Brooke Parsons<\/h3>\n

Consumer Consultant, The Florey<\/p>\n

[\/et_pb_text][et_pb_social_media_follow _builder_version=”4.27.4″ _module_preset=”default” locked=”off” global_colors_info=”{}”][et_pb_social_media_follow_network social_network=”linkedin” url=”https:\/\/www.linkedin.com\/in\/brooke-parsons-815172197\/” _builder_version=”4.27.4″ _module_preset=”default” background_color=”#DC6B5B” background_enable_color=”on” global_colors_info=”{}” icon_color__hover_enabled=”off|desktop” background__hover_enabled=”on|hover” background_color__hover=”#8ABCBB” background_enable_color__hover=”on” follow_button=”off” url_new_window=”on”]linkedin[\/et_pb_social_media_follow_network][\/et_pb_social_media_follow][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” link_font=”||||on|||#DC6B5B|” link_text_color=”#002933″ global_colors_info=”{}”]Brooke Parsons is a Consumer Consultant at the Florey Institute of Neuroscience and Mental Health, where she works alongside researchers to embed lived experience into stroke research and translation. A stroke survivor since the age of 13, Brooke has undergone more than 100 surgeries and lives with complex health conditions including POTS, and Middleton\u2019s Syndrome. Drawing on over three decades of lived experience, she brings a unique perspective to national and international projects such as AVERT, AVERT Dose, PESTO and the Young Stroke Service. Brooke is also a sought-after speaker at conferences including the World Stroke Congress 2023, Smart Strokes 2024 and ANZSOC 2025. She embraces the mantra \u201cGreater than stroke\u201d as a symbol of resilience, advocacy, and the power of consumer voices in shaping research and care.[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ disabled_on=”on|on|on” module_id=”catherene-pham” _builder_version=”4.27.4″ _module_preset=”default” custom_margin=”||0px||false|false” custom_padding=”||0px||false|false” disabled=”on” global_colors_info=”{}”][et_pb_row column_structure=”1_4,3_4″ use_custom_gutter=”on” gutter_width=”2″ _builder_version=”4.27.4″ _module_preset=”default” custom_margin=”0px||0px||true|false” custom_padding=”0px||0px||true|false” global_colors_info=”{}”][et_pb_column type=”1_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_image src=”https:\/\/braintechaustralia.com.au\/2025\/wp-content\/uploads\/2025\/10\/braintech-2025-speakers-catherene-pham-500px.jpg” alt=”Catherene Pham” title_text=”Catherene Pham” _builder_version=”4.27.4″ _module_preset=”default” border_width_all=”5px” border_color_all=”#CCE8E9″ global_colors_info=”{}”][\/et_pb_image][\/et_pb_column][et_pb_column type=”3_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” text_font=”|600|||||||” text_text_color=”#002933″ header_3_font=”|700||on|||||” header_3_text_color=”#DC6B5B” custom_margin=”||0px||false|false” custom_padding=”||0px||false|false” global_colors_info=”{}”]<\/p>\n

\u200bDr Catherene Pham<\/h3>\n

Inventor of NEUROsense<\/p>\n

[\/et_pb_text][et_pb_social_media_follow _builder_version=”4.27.4″ _module_preset=”default” locked=”off” global_colors_info=”{}”][et_pb_social_media_follow_network social_network=”linkedin” url=”https:\/\/www.linkedin.com\/in\/drcatherenecjp\/” _builder_version=”4.27.4″ _module_preset=”default” background_color=”#DC6B5B” background_enable_color=”on” global_colors_info=”{}” icon_color__hover_enabled=”off|desktop” background__hover_enabled=”on|hover” background_color__hover=”#8ABCBB” background_enable_color__hover=”on” follow_button=”off” url_new_window=”on”]linkedin[\/et_pb_social_media_follow_network][\/et_pb_social_media_follow][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” link_font=”||||on|||#DC6B5B|” link_text_color=”#002933″ global_colors_info=”{}”]Dr. Catherene CJ Pham is a healthcare specialist, corporate governance professional, and deep-tech executive with over 25 years of clinical experience. She holds expertise as a Certified Consultant in Data, AI, Cyber Security, and Digital Transformation. She serves as a Board Director for the Victorian Department of Health. As the Founder and Chief Executive Officer of BioPhamTech Group Pty Ltd, she spearheads an AI-enhanced digital health tech startup, passionately driving a vision for health equity for women and underrepresented individuals in the community.<\/p>\n

A distinguished global clinician, Dr. Pham is a strategic thought leader and inventor of NEUROsense, an integrated predictive AI platform for women\u2019s health hormones and Alzheimer\u2019s cognitive continuous monitoring for personalised longitudinal health dataset screening 20 years before symptoms and irreversible symptoms of Alzheimer’s. This is a revolutionary paradigm shift urgently needed to tackle the $1 trillion Gender Health Gap for women globally. BioPhamTech is collaborating with Monash University for its research and commercialisation. Her innovative work also includes SMILEShield, a dental nanotechnology aimed at the eradication of tooth decay. [\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ module_id=”harikesh-pushpapathan” _builder_version=”4.27.4″ _module_preset=”default” custom_margin=”||0px||false|false” custom_padding=”||0px||false|false” global_colors_info=”{}”][et_pb_row column_structure=”1_4,3_4″ use_custom_gutter=”on” gutter_width=”2″ _builder_version=”4.27.4″ _module_preset=”default” custom_margin=”0px||0px||true|false” custom_padding=”0px||0px||true|false” global_colors_info=”{}”][et_pb_column type=”1_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_image src=”https:\/\/braintechaustralia.com.au\/2025\/wp-content\/uploads\/2025\/06\/braintech-2025-speakers-harikesh-pushpapathan-500px.jpg” alt=”Harikesh Pushpapathan” title_text=”Harikesh Pushpapathan” _builder_version=”4.27.4″ _module_preset=”default” border_width_all=”5px” border_color_all=”#CCE8E9″ global_colors_info=”{}”][\/et_pb_image][\/et_pb_column][et_pb_column type=”3_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” text_font=”|600|||||||” text_text_color=”#002933″ header_3_font=”|700||on|||||” header_3_text_color=”#DC6B5B” custom_margin=”||0px||false|false” custom_padding=”||0px||false|false” global_colors_info=”{}”]<\/p>\n

Harikesh Pushpapathan<\/h3>\n

General Partner, Stoic VC<\/p>\n

[\/et_pb_text][et_pb_social_media_follow _builder_version=”4.27.4″ _module_preset=”default” locked=”off” global_colors_info=”{}”][et_pb_social_media_follow_network social_network=”linkedin” url=”https:\/\/www.linkedin.com\/in\/harikesh-pushpapathan” _builder_version=”4.27.4″ _module_preset=”default” background_color=”#DC6B5B” background_enable_color=”on” global_colors_info=”{}” icon_color__hover_enabled=”off|desktop” background__hover_enabled=”on|hover” background_color__hover=”#8ABCBB” background_enable_color__hover=”on” follow_button=”off” url_new_window=”on”]linkedin[\/et_pb_social_media_follow_network][\/et_pb_social_media_follow][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” link_font=”||||on|||#DC6B5B|” link_text_color=”#002933″ global_colors_info=”{}”]<\/p>\n

Partner @ Stoic VC<\/a>; an early stage venture fund solving our world\u2019s most intractable problems by a) Redesigning human health b) supercharging compute c) rebalancing the earth. To do this, we partner with Uniseed – commercialisation body managing 65% of Australia R&D output. I currently sit on a few committees including Uniseed, Antler and NSW government’s Biosciences fund. Prior to this, I spent a few years investing personally, at other funds, fundraising for startups and building my own telehealth business. When I\u2019m not investing or recovering from sporting injuries, I love to write – both in music and blogs.<\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ module_id=”lianne-schmaal” _builder_version=”4.27.4″ _module_preset=”default” custom_margin=”||0px||false|false” custom_padding=”||0px||false|false” global_colors_info=”{}”][et_pb_row column_structure=”1_4,3_4″ use_custom_gutter=”on” gutter_width=”2″ _builder_version=”4.27.4″ _module_preset=”default” custom_margin=”0px||0px||true|false” custom_padding=”0px||0px||true|false” global_colors_info=”{}”][et_pb_column type=”1_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_image src=”https:\/\/braintechaustralia.com.au\/2025\/wp-content\/uploads\/2025\/09\/braintech-2025-speakers-lianne-schmaal-500px.jpg” alt=”Lianne Schmaal” title_text=”Lianne Schmaal” _builder_version=”4.27.4″ _module_preset=”default” border_width_all=”5px” border_color_all=”#CCE8E9″ global_colors_info=”{}”][\/et_pb_image][\/et_pb_column][et_pb_column type=”3_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” text_font=”|600|||||||” text_text_color=”#002933″ header_3_font=”|700||on|||||” header_3_text_color=”#DC6B5B” custom_margin=”||0px||false|false” custom_padding=”||0px||false|false” global_colors_info=”{}”]<\/p>\n

Professor Lianne Schmaal<\/h3>\n

Head of the Mood and Anxiety Disorders Research program, Orygen, The University of Melbourne<\/p>\n

[\/et_pb_text][et_pb_social_media_follow _builder_version=”4.27.4″ _module_preset=”default” locked=”off” global_colors_info=”{}”][et_pb_social_media_follow_network social_network=”linkedin” url=”https:\/\/www.linkedin.com\/in\/lianne-schmaal-4416a520\/” _builder_version=”4.27.4″ _module_preset=”default” background_color=”#DC6B5B” background_enable_color=”on” global_colors_info=”{}” icon_color__hover_enabled=”off|desktop” background__hover_enabled=”on|hover” background_color__hover=”#8ABCBB” background_enable_color__hover=”on” follow_button=”off” url_new_window=”on”]linkedin[\/et_pb_social_media_follow_network][\/et_pb_social_media_follow][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” link_font=”||||on|||#DC6B5B|” link_text_color=”#002933″ global_colors_info=”{}”]Professor Lianne Schmaal is an NHMRC Investigator and a Dame Kate Campbell fellow for Research Excellence. Lianne\u2019s work covers a broad spectrum of research ranging from identifying mechanisms underlying mood and anxiety disorders to trialling novel treatments.<\/p>\n

A key focus of her research is on understanding the mechanisms underlying the onset and course trajectories of depression, anxiety and suicidal thoughts and behaviours and their response to treatment. It also identifies who is at risk for poor long-term outcomes.<\/p>\n

Her team integrates clinical, psychosocial, neurobiological and genetic data using machine learning methods to develop prediction models for illness onset and progression, treatment response and suicide attempts. This work also identifies subgroups of people within and across these disorders who have unique symptoms or biological profiles.<\/p>\n

Lianne also leads the two largest neuroimaging consortia on depression and suicidal behaviours worldwide, the ENIGMA Major Depressive Disorder and the ENIGMA Suicidal Thoughts and Behaviours consortia. These international consortia pool neuroimaging and clinical data from more than 50,000 people from approximately 50 research institutes in 16 different countries worldwide.[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ module_id=”camille-shanahan” _builder_version=”4.27.4″ _module_preset=”default” custom_margin=”||0px||false|false” custom_padding=”||0px||false|false” global_colors_info=”{}”][et_pb_row column_structure=”1_4,3_4″ use_custom_gutter=”on” gutter_width=”2″ _builder_version=”4.27.4″ _module_preset=”default” custom_margin=”0px||0px||true|false” custom_padding=”0px||0px||true|false” global_colors_info=”{}”][et_pb_column type=”1_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_image src=”https:\/\/braintechaustralia.com.au\/2025\/wp-content\/uploads\/2025\/10\/braintech-2025-speakers-camille-shanahan-500px.jpg” alt=”Camille Shanahan” title_text=”Camille Shanahan” _builder_version=”4.27.4″ _module_preset=”default” border_width_all=”5px” border_color_all=”#CCE8E9″ global_colors_info=”{}”][\/et_pb_image][\/et_pb_column][et_pb_column type=”3_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” text_font=”|600|||||||” text_text_color=”#002933″ header_3_font=”|700||on|||||” header_3_text_color=”#DC6B5B” custom_margin=”||0px||false|false” custom_padding=”||0px||false|false” global_colors_info=”{}”]<\/p>\n

Camille Shanahan<\/h3>\n

General Manager, Jumar Bioincubator<\/p>\n

[\/et_pb_text][et_pb_social_media_follow _builder_version=”4.27.4″ _module_preset=”default” locked=”off” global_colors_info=”{}”][et_pb_social_media_follow_network social_network=”linkedin” url=”https:\/\/www.linkedin.com\/in\/camilleshanahan\/” _builder_version=”4.27.4″ _module_preset=”default” background_color=”#DC6B5B” background_enable_color=”on” global_colors_info=”{}” icon_color__hover_enabled=”off|desktop” background__hover_enabled=”on|hover” background_color__hover=”#8ABCBB” background_enable_color__hover=”on” follow_button=”off” url_new_window=”on”]linkedin[\/et_pb_social_media_follow_network][\/et_pb_social_media_follow][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” link_font=”||||on|||#DC6B5B|” link_text_color=”#002933″ global_colors_info=”{}”]Camille Shanahan manages Jumar Bioincubator to ensure there is a thriving biotech community of diverse biopharma and medtech startups with the support they need to accelerate product
\ndevelopment. She leads the Jumar Bioincubator team, maintains connections with all
\nresidents and across the ecosystem and curates the events and programs to create a culture of
\ninnovation and acceleration – driving Jumar\u2019s contribution to the broader medtech and
\npharmaceutical ecosystem in Australia.<\/p>\n

Camille has experience across clinical, scientific, business development and commercialisation
\nroles in the biopharma sector, working in Australia and Canada. She has built on her
\nacademic medical research experience to facilitate the translation of Australia\u2019s world class
\nresearch into clinical solutions. Camille has a strong track record in managing projects in early
\nstage translational, STEM infrastructure and health policy. Prior to joining Jumar Bio Camille
\nheld life sciences consulting and business development roles developing strong ties with
\nbiotech companies at all stages of product development and with key peak bodies including
\nAusbiotech, MTPConnect and BioMelbourne Network.[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ module_id=”avinash-singh” _builder_version=”4.27.4″ _module_preset=”default” custom_margin=”||0px||false|false” custom_padding=”||0px||false|false” global_colors_info=”{}”][et_pb_row column_structure=”1_4,3_4″ use_custom_gutter=”on” gutter_width=”2″ _builder_version=”4.27.4″ _module_preset=”default” custom_margin=”0px||0px||true|false” custom_padding=”0px||0px||true|false” global_colors_info=”{}”][et_pb_column type=”1_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_image src=”https:\/\/braintechaustralia.com.au\/2025\/wp-content\/uploads\/2025\/10\/braintech-2025-speakers-avinash-singh-500px.jpg” alt=”Avinash Singh” title_text=”Avinash Singh” _builder_version=”4.27.4″ _module_preset=”default” border_width_all=”5px” border_color_all=”#CCE8E9″ global_colors_info=”{}”][\/et_pb_image][\/et_pb_column][et_pb_column type=”3_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” text_font=”|600|||||||” text_text_color=”#002933″ header_3_font=”|700||on|||||” header_3_text_color=”#DC6B5B” custom_margin=”||0px||false|false” custom_padding=”||0px||false|false” global_colors_info=”{}”]<\/p>\n

Dr Avinash Singh<\/h3>\n

Senior Lecturer, School of Computer Science, University of Technology Sydney[\/et_pb_text][et_pb_social_media_follow _builder_version=”4.27.4″ _module_preset=”default” locked=”off” global_colors_info=”{}”][et_pb_social_media_follow_network social_network=”linkedin” url=”https:\/\/www.linkedin.com\/in\/avinashks\/” _builder_version=”4.27.4″ _module_preset=”default” background_color=”#DC6B5B” background_enable_color=”on” global_colors_info=”{}” icon_color__hover_enabled=”off|desktop” background__hover_enabled=”on|hover” background_color__hover=”#8ABCBB” background_enable_color__hover=”on” follow_button=”off” url_new_window=”on”]linkedin[\/et_pb_social_media_follow_network][\/et_pb_social_media_follow][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” link_font=”||||on|||#DC6B5B|” link_text_color=”#002933″ global_colors_info=”{}”]Dr Avinash Singh serves as a co-chair of the IEEE Neuroethics Framework for the Workplace, sponsored by IEEE Brain, a member of the IEEE Standards Committee on Unifying Brain-Computer Interfaces (BCI) and an expert panel on Institute of Neurotechnology and Law, UK. In 2021, he was awarded the Google TensorFlow Faculty Award to support and promote his work in BCI. Additionally, he actively advocates for and supports transhumanism and founded the India Future Society, a think tank. And he recently joined UNICEF as an expert advisor on neurotech for children. <\/p>\n

Dr Singh completed his PhD in Computer Science in 2019 at UTS, Australia, collaborating with the Technical University of Berlin, Germany, the University of California San Diego, USA and the US Army Research Lab. Before earning his doctorate, he received a Master’s in Software Systems in 2013 from Birla Institute of Technology and Science Pilani, India.<\/p>\n

Working at the intersection of machine learning, cognitive neuroscience, and mixed-reality, Dr. Singh is dedicated to designing and developing real-world neuroadaptive BCI systems. His current research interests include integrating artificial intelligence (AI) technologies with cognitive neuroscience knowledge to explore cognitive functions, discover relationships between brain dynamics, evaluate everyday interactions and make decisions to develop robust next-generation neuroadaptive BCIs.[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ module_id=”rachel-slattery” _builder_version=”4.27.4″ _module_preset=”default” custom_margin=”||0px||false|false” custom_padding=”||0px||false|false” global_colors_info=”{}”][et_pb_row column_structure=”1_4,3_4″ use_custom_gutter=”on” gutter_width=”2″ _builder_version=”4.27.4″ _module_preset=”default” custom_margin=”0px||0px||true|false” custom_padding=”0px||0px||true|false” global_colors_info=”{}”][et_pb_column type=”1_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_image src=”https:\/\/braintechaustralia.com.au\/2025\/wp-content\/uploads\/2025\/10\/slatterys-headshots-web-rachel-slattery-009-500px.jpg” alt=”Rachel Slattery” title_text=”Rachel Slattery” _builder_version=”4.27.4″ _module_preset=”default” border_width_all=”5px” border_color_all=”#CCE8E9″ global_colors_info=”{}”][\/et_pb_image][\/et_pb_column][et_pb_column type=”3_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” text_font=”|600|||||||” text_text_color=”#002933″ header_3_font=”|700||on|||||” header_3_text_color=”#DC6B5B” custom_margin=”||0px||false|false” custom_padding=”||0px||false|false” global_colors_info=”{}”]<\/p>\n

Rachel Slattery<\/h3>\n

Director, Slatterys<\/p>\n

[\/et_pb_text][et_pb_social_media_follow _builder_version=”4.27.4″ _module_preset=”default” locked=”off” global_colors_info=”{}”][et_pb_social_media_follow_network social_network=”linkedin” url=”https:\/\/www.linkedin.com\/in\/rachel-slattery-11209017\/” _builder_version=”4.27.4″ _module_preset=”default” background_color=”#DC6B5B” background_enable_color=”on” global_colors_info=”{}” icon_color__hover_enabled=”off|desktop” background__hover_enabled=”on|hover” background_color__hover=”#8ABCBB” background_enable_color__hover=”on” follow_button=”off” url_new_window=”on”]linkedin[\/et_pb_social_media_follow_network][\/et_pb_social_media_follow][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” link_font=”||||on|||#DC6B5B|” link_text_color=”#002933″ global_colors_info=”{}”]<\/p>\n

Rachel Slattery, with the help of her team, creates and nourishes communities of curious minds around frontier tech and better ways of working. She is recognised for founding iconic gatherings such as Tech23 and Agile Australia, which have helped shape Australia’s innovation and technology landscape. Passionate about helping increase our healthspans, Rachel has recently launched Silver Futures<\/a><\/em> – a new initiative rethinking how we approach the second half of our lives to ensure longer, healthier, and more fulfilling futures.<\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ module_id=”tina-soulis” _builder_version=”4.27.4″ _module_preset=”default” custom_margin=”||0px||false|false” custom_padding=”||0px||false|false” global_colors_info=”{}”][et_pb_row column_structure=”1_4,3_4″ use_custom_gutter=”on” gutter_width=”2″ _builder_version=”4.27.4″ _module_preset=”default” custom_margin=”0px||0px||true|false” custom_padding=”0px||0px||true|false” global_colors_info=”{}”][et_pb_column type=”1_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_image src=”https:\/\/braintechaustralia.com.au\/2025\/wp-content\/uploads\/2025\/10\/braintech-2025-speakers-tina-soulis-500px.jpg” alt=”Tina Soulis” title_text=”Tina Soulis” _builder_version=”4.27.4″ _module_preset=”default” border_width_all=”5px” border_color_all=”#CCE8E9″ global_colors_info=”{}”][\/et_pb_image][\/et_pb_column][et_pb_column type=”3_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” text_font=”|600|||||||” text_text_color=”#002933″ header_3_font=”|700||on|||||” header_3_text_color=”#DC6B5B” custom_margin=”||0px||false|false” custom_padding=”||0px||false|false” global_colors_info=”{}”]<\/p>\n

A\/Prof Tina Soulis, Ph.D.<\/h3>\n

Founder and Director, Alithia Life Sciences<\/p>\n

[\/et_pb_text][et_pb_social_media_follow _builder_version=”4.27.4″ _module_preset=”default” locked=”off” global_colors_info=”{}”][et_pb_social_media_follow_network social_network=”linkedin” url=”https:\/\/www.linkedin.com\/in\/tina-soulis\/” _builder_version=”4.27.4″ _module_preset=”default” background_color=”#DC6B5B” background_enable_color=”on” global_colors_info=”{}” icon_color__hover_enabled=”off|desktop” background__hover_enabled=”on|hover” background_color__hover=”#8ABCBB” background_enable_color__hover=”on” follow_button=”off” url_new_window=”on”]linkedin[\/et_pb_social_media_follow_network][\/et_pb_social_media_follow][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” link_font=”||||on|||#DC6B5B|” link_text_color=”#002933″ global_colors_info=”{}”]A\/Prof Tina Soulis, Ph.D., is Founder and Director of Alithia Life Sciences, an Australian-owned full-service clinical research organization (CRO) supporting global biopharmaceutical, medtech, and research clients with operational excellence across early- and late-phase studies. With over 30 years of leadership in clinical trials, biotechnology, and academic research, she is also Strategic Advisor to Kinoxis Therapeutics and a Portfolio Australian Director for multiple international biotech entities.<\/p>\n

Dr. Soulis earned her Ph.D. in Medicine from the University of Melbourne, where her research focused on the role of advanced glycation end products in diabetic complications. She also holds a B.Sc. in Biochemistry and Medicine. Throughout her career, she has held executive roles including CEO of Neuroscience Trials Australia\u2014where she grew the business by 39% annually and Director of Clinical Development for an ASX200 biotech company, where she led programs from lab through global regulatory approval.<\/p>\n

A clinical trial expert across therapeutic areas including neuroscience, oncology, endocrinology, rare and pediatric diseases, and medical devices, Dr. Soulis has built Alithia into a bespoke, high-integrity CRO known for zero staff turnover and seamless global execution. She is one of the few Australian leaders to have successfully taken multiple products from preclinical research to licensing and commercialization.<\/p>\n

An advocate for the Australian R&D ecosystem, Dr. Soulis holds academic appointments at the University of Melbourne and serves as a mentor to emerging industry professionals. She is a sought-after global speaker on clinical strategy, innovation, and research-commercialization pathways\u2014combining scientific rigor with entrepreneurial vision to deliver lasting impact in healthcare.[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ module_id=”jeremy-steele” _builder_version=”4.27.4″ _module_preset=”default” custom_margin=”||0px||false|false” custom_padding=”||0px||false|false” global_colors_info=”{}”][et_pb_row column_structure=”1_4,3_4″ use_custom_gutter=”on” gutter_width=”2″ _builder_version=”4.27.4″ _module_preset=”default” custom_margin=”0px||0px||true|false” custom_padding=”0px||0px||true|false” global_colors_info=”{}”][et_pb_column type=”1_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_image src=”https:\/\/braintechaustralia.com.au\/2025\/wp-content\/uploads\/2025\/09\/braintech-2025-speakers-jeremy-steele-500px.jpg” alt=”Jeremy Steele” title_text=”Jeremy Steele” _builder_version=”4.27.4″ _module_preset=”default” border_width_all=”5px” border_color_all=”#CCE8E9″ global_colors_info=”{}”][\/et_pb_image][\/et_pb_column][et_pb_column type=”3_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” text_font=”|600|||||||” text_text_color=”#002933″ header_3_font=”|700||on|||||” header_3_text_color=”#DC6B5B” custom_margin=”||0px||false|false” custom_padding=”||0px||false|false” global_colors_info=”{}”]<\/p>\n

Jeremy Steele<\/h3>\n

CEO, Control Bionics<\/strong><\/p>\n

[\/et_pb_text][et_pb_social_media_follow _builder_version=”4.27.4″ _module_preset=”default” locked=”off” global_colors_info=”{}”][et_pb_social_media_follow_network social_network=”linkedin” url=”https:\/\/www.linkedin.com\/in\/jeremy-steele-a9101926\/” _builder_version=”4.27.4″ _module_preset=”default” background_color=”#DC6B5B” background_enable_color=”on” global_colors_info=”{}” icon_color__hover_enabled=”off|desktop” background__hover_enabled=”on|hover” background_color__hover=”#8ABCBB” background_enable_color__hover=”on” follow_button=”off” url_new_window=”on”]linkedin[\/et_pb_social_media_follow_network][\/et_pb_social_media_follow][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” link_font=”||||on|||#DC6B5B|” link_text_color=”#002933″ global_colors_info=”{}”]Jeremy Steele is the CEO of Control Bionics (ASX:CBL), arguably a global leader in neurotechnology dedicated to empowering people with severe disabilities and advancing human performance. With a focus on translating cutting-edge neuroscience into practical solutions, Jeremy has driven Control Bionics\u2019 evolution from a pioneering assistive communication company into a broader neurotech innovator spanning assistive communication, rehabilitation, and sports performance.<\/p>\n

Under his leadership, the company has expanded its portfolio beyond its flagship NeuroNode sEMG device \u2013 an FDA-cleared, Class II device that transforms tiny neural signals into communication \u2013 to include NeuroStrip, a next-generation wearable EMG platform, and NeuroBounce, a performance-based program enhancing athletic explosiveness and recovery.<\/p>\n

Jeremy brings over two decades of executive leadership experience across healthcare, technology, and growth-stage companies. He is passionate about bridging science, technology, and human potential \u2013 whether by giving a voice to people living with conditions such as cerebral palsy and ALS\/MND, or by unlocking new ways to measure and improve human performance.<\/p>\n

Guided by a mission to put neurotechnology in the hands of those who need it most, Jeremy continues to lead Control Bionics in forging partnerships with clinicians, researchers, sports organisations, and investors worldwide.[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ module_id=”qiang-sun” _builder_version=”4.27.4″ _module_preset=”default” custom_margin=”||0px||false|false” custom_padding=”||0px||false|false” global_colors_info=”{}”][et_pb_row column_structure=”1_4,3_4″ use_custom_gutter=”on” gutter_width=”2″ _builder_version=”4.27.4″ _module_preset=”default” custom_margin=”0px||0px||true|false” custom_padding=”0px||0px||true|false” global_colors_info=”{}”][et_pb_column type=”1_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_image src=”https:\/\/braintechaustralia.com.au\/2025\/wp-content\/uploads\/2025\/09\/braintech-2025-speakers-qiang-sun-500px.jpg” alt=”Qiang Sun” title_text=”Qiang Sun” _builder_version=”4.27.4″ _module_preset=”default” border_width_all=”5px” border_color_all=”#CCE8E9″ global_colors_info=”{}”][\/et_pb_image][\/et_pb_column][et_pb_column type=”3_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” text_font=”|600|||||||” text_text_color=”#002933″ header_3_font=”|700||on|||||” header_3_text_color=”#DC6B5B” custom_margin=”||0px||false|false” custom_padding=”||0px||false|false” global_colors_info=”{}”]<\/p>\n

Dr Qiang Sun<\/h3>\n

Research Fellow, Department of Physics, RMIT University<\/strong><\/p>\n

[\/et_pb_text][et_pb_social_media_follow _builder_version=”4.27.4″ _module_preset=”default” locked=”off” global_colors_info=”{}”][et_pb_social_media_follow_network social_network=”linkedin” url=”https:\/\/www.linkedin.com\/in\/sq-ric\/” _builder_version=”4.27.4″ _module_preset=”default” background_color=”#DC6B5B” background_enable_color=”on” global_colors_info=”{}” icon_color__hover_enabled=”off|desktop” background__hover_enabled=”on|hover” background_color__hover=”#8ABCBB” background_enable_color__hover=”on” follow_button=”off” url_new_window=”on”]linkedin[\/et_pb_social_media_follow_network][\/et_pb_social_media_follow][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” link_font=”||||on|||#DC6B5B|” link_text_color=”#002933″ global_colors_info=”{}”]Dr Qiang Sun is a Research Fellow in the Department of Physics at RMIT University, specialising in quantum sensing, optics, and computational electromagnetics. His research focuses on developing quantum technologies that detect the brain\u2019s faint magnetic fields using diamond-based sensors, enabling new forms of portable neuroimaging.<\/p>\n

Qiang led the computational research for the Critical Technologies Challenge Program project \u201cScanning the Brain on the Move,\u201d which aims to create next-generation portable MEG systems for healthcare and rural applications. His work combines high-performance computation, physics, and sensor engineering to bridge the gap between laboratory research and clinical practice.<\/p>\n

Through collaborations across Australia, the United States, Europe, and Asia, Qiang has advanced methods in electromagnetic simulation, nanoscale sensing, and brain imaging. He works closely with partners including Swinburne University of Technology and Phasor Innovation.<\/p>\n

He is passionate about translating quantum and computational physics into practical tools that improve human health and deepen our understanding of the brain.[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ module_id=”kathryn-sunn” _builder_version=”4.27.4″ _module_preset=”default” custom_margin=”||0px||false|false” custom_padding=”||0px||false|false” global_colors_info=”{}”][et_pb_row column_structure=”1_4,3_4″ use_custom_gutter=”on” gutter_width=”2″ _builder_version=”4.27.4″ _module_preset=”default” custom_margin=”0px||0px||true|false” custom_padding=”0px||0px||true|false” global_colors_info=”{}”][et_pb_column type=”1_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_image src=”https:\/\/braintechaustralia.com.au\/2025\/wp-content\/uploads\/2025\/07\/braintech-2025-speakers-kathryn-sunn-500px.jpg” alt=”Kathryn Sunn” title_text=”Kathryn Sunn” _builder_version=”4.27.4″ _module_preset=”default” border_width_all=”5px” border_color_all=”#CCE8E9″ global_colors_info=”{}”][\/et_pb_image][\/et_pb_column][et_pb_column type=”3_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” text_font=”|600|||||||” text_text_color=”#002933″ header_3_font=”|700||on|||||” header_3_text_color=”#DC6B5B” custom_margin=”||0px||false|false” custom_padding=”||0px||false|false” global_colors_info=”{}”]<\/p>\n

Dr Kathryn Sunn<\/h3>\n

CEO, Celosia Therapeutics and Director of Commercialisation, Macquarie University<\/p>\n

[\/et_pb_text][et_pb_social_media_follow _builder_version=”4.27.4″ _module_preset=”default” locked=”off” global_colors_info=”{}”][et_pb_social_media_follow_network social_network=”linkedin” url=”https:\/\/linkedin.com\/in\/kathrynsunn” _builder_version=”4.27.4″ _module_preset=”default” background_color=”#DC6B5B” background_enable_color=”on” global_colors_info=”{}” icon_color__hover_enabled=”off|desktop” background__hover_enabled=”on|hover” background_color__hover=”#8ABCBB” background_enable_color__hover=”on” follow_button=”off” url_new_window=”on”]linkedin[\/et_pb_social_media_follow_network][\/et_pb_social_media_follow][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” link_font=”||||on|||#DC6B5B|” link_text_color=”#002933″ global_colors_info=”{}”]Celosia Therapeutics is a pre-clinical stage gene therapy company, developing solutions for neurodegenerative diseases that have limited alternative therapeutic options.<\/p>\n

Dr. Sunn is renowned for her dynamic leadership and strategic vision in fostering technology collaborations and expanding commercial opportunities within the Australian research and early enterprise sectors. With extensive experience in intellectual property management, strategy, and business development, Dr. Sunn has held roles in two of Australia\u2019s leading patent firms and has spearheaded the technology transfer units at the Australia\u2019s largest universities. Her expertise lies in forging impactful strategic partnerships and delivering commercially focused advice to transform innovations into valuable assets.<\/p>\n

Dr. Sunn holds a PhD in Medical Science with a specialisation in genetics from the Garvan Institute of Medical Research. She is a trained patent and trademark attorney in Australia and New Zealand. serving She is on the Board of Knowledge Commercialisation Australasia as well as on the boards of several Macquarie University startup companies.[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ module_id=”cassandra-szoeke” _builder_version=”4.27.4″ _module_preset=”default” custom_margin=”||0px||false|false” custom_padding=”||0px||false|false” global_colors_info=”{}”][et_pb_row column_structure=”1_4,3_4″ use_custom_gutter=”on” gutter_width=”2″ _builder_version=”4.27.4″ _module_preset=”default” custom_margin=”0px||0px||true|false” custom_padding=”0px||0px||true|false” global_colors_info=”{}”][et_pb_column type=”1_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_image src=”https:\/\/braintechaustralia.com.au\/2025\/wp-content\/uploads\/2025\/06\/braintech-2025-speakers-cassandra-szoeke-500px.jpg” alt=”Cassandra Szoeke” title_text=”Cassandra Szoeke” _builder_version=”4.27.4″ _module_preset=”default” border_width_all=”5px” border_color_all=”#CCE8E9″ global_colors_info=”{}”][\/et_pb_image][\/et_pb_column][et_pb_column type=”3_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” text_font=”|600|||||||” text_text_color=”#002933″ header_3_font=”|700||on|||||” header_3_text_color=”#DC6B5B” custom_margin=”||0px||false|false” custom_padding=”||0px||false|false” global_colors_info=”{}”]<\/p>\n

Professor Cassandra Szoeke<\/h3>\n

Lead, Women’s Healthy Ageing Program, Monash Centre for Health Research<\/p>\n

[\/et_pb_text][et_pb_social_media_follow _builder_version=”4.27.4″ _module_preset=”default” locked=”off” global_colors_info=”{}”][et_pb_social_media_follow_network social_network=”linkedin” url=”https:\/\/www.linkedin.com\/in\/drcsz” _builder_version=”4.27.4″ _module_preset=”default” background_color=”#DC6B5B” background_enable_color=”on” global_colors_info=”{}” icon_color__hover_enabled=”off|desktop” background__hover_enabled=”on|hover” background_color__hover=”#8ABCBB” background_enable_color__hover=”on” follow_button=”off” url_new_window=”on”]linkedin[\/et_pb_social_media_follow_network][\/et_pb_social_media_follow][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”]Professor Cassandra Szoeke is a Consultant Neurologist, Author and Internationally awarded Academic. In addition to her medical qualifications and fellowship in the Royal College of Physicians she has a BSc with Honours in Genetics and PhD in Epidemiology, her postdoctoral studies at Stanford University CA, focused on public health and policy and her sabbatical at Oxford University focused on sex-specific medicine. <\/p>\n

Cassandra is is the Inaugural Chair of the Asia-Pacific Node of the Women\u2019s Brain Project. She has contributed to the development of national health policies, has sat on the Council of the Australian Medical Association, was appointed to Medical Panels by the Department of Health (Victoria) and has held Chief Health Advisor roles for the Australian Healthy Ageing Organisation and the National Council of Women.[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ disabled_on=”on|on|on” module_id=”chris-vindurampulle” _builder_version=”4.27.4″ _module_preset=”default” custom_margin=”||0px||false|false” custom_padding=”||0px||false|false” disabled=”on” global_colors_info=”{}”][et_pb_row column_structure=”1_4,3_4″ use_custom_gutter=”on” gutter_width=”2″ _builder_version=”4.27.4″ _module_preset=”default” custom_margin=”0px||0px||true|false” custom_padding=”0px||0px||true|false” global_colors_info=”{}”][et_pb_column type=”1_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_column][et_pb_column type=”3_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” text_font=”|600|||||||” text_text_color=”#002933″ header_3_font=”|700||on|||||” header_3_text_color=”#DC6B5B” custom_margin=”||0px||false|false” custom_padding=”||0px||false|false” global_colors_info=”{}”]<\/p>\n

Dr Chris Vindurampulle<\/h3>\n

Principal, Griffith Hack<\/p>\n

[\/et_pb_text][et_pb_social_media_follow _builder_version=”4.27.4″ _module_preset=”default” locked=”off” global_colors_info=”{}”][et_pb_social_media_follow_network social_network=”linkedin” url=”https:\/\/www.linkedin.com\/in\/chris-vindurampulle\/” _builder_version=”4.27.4″ _module_preset=”default” background_color=”#DC6B5B” background_enable_color=”on” global_colors_info=”{}” icon_color__hover_enabled=”off|desktop” background__hover_enabled=”on|hover” background_color__hover=”#8ABCBB” background_enable_color__hover=”on” follow_button=”off” url_new_window=”on”]linkedin[\/et_pb_social_media_follow_network][\/et_pb_social_media_follow][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n

Bio pending<\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_row _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.27.4″ _module_preset=”default” background_color=”#002933″ custom_margin=”||0px||false|false” custom_padding=”||0px||false|false” global_module=”2498″ global_colors_info=”{}”][et_pb_row _builder_version=”4.27.4″ _module_preset=”default” custom_padding=”0px||||false|false” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.25.1″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” text_font=”|–et_global_body_font_weight|||||||” text_text_color=”#FFFFFF” header_4_font=”||||||||” header_5_font=”|700|||||||” global_colors_info=”{}”]<\/p>\n

TeamSlatts who is convening BrainTech 2025 acknowledges the Traditional Owners of the Countries on which we gather for our events. We recognise the sovereignty, knowledge and community of First Peoples and pay our respects to the Ancestors and Elders who pave the way for future Leaders.<\/p>\n

We walk with great reverence on the various places TeamSlatts live, work and visit. Always was, always will be.<\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=”1_4,3_4″ make_equal=”on” _builder_version=”4.27.4″ _module_preset=”default” custom_padding=”||0px||false|false” custom_css_main_element=”align-items:center;” border_width_top=”1px” border_color_top=”#CCE8E9″ global_colors_info=”{}”][et_pb_column type=”1_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_image src=”https:\/\/braintechaustralia.com.au\/2025\/wp-content\/uploads\/2025\/06\/braintech-2025-logo-sf-300x28px.png” title_text=”braintech-2025-logo-sf-300x28px” _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_image][\/et_pb_column][et_pb_column type=”3_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” text_font=”|–et_global_body_font_weight|||||||” text_text_color=”#DC6B5B” link_font=”||||||||” link_text_color=”#FFFFFF” header_4_font=”||||||||” header_5_font=”|700|||||||” global_colors_info=”{}”]Silver Futures<\/a> \u2022 Slatterys<\/a> \u2022 Contact Us<\/a> \u2022 Privacy Policy<\/a> \u2022 Community Charter<\/a>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"

Hear from researchers and innovators leading the way at BrainTech 2025!<\/p>\n","protected":false},"author":5,"featured_media":2382,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"dipi_cpt_category":[],"class_list":["post-2302","page","type-page","status-publish","has-post-thumbnail","hentry"],"yoast_head":"\nSpeakers - BrainTech 2025<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/braintechaustralia.com.au\/2025\/speakers\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Speakers - BrainTech 2025\" \/>\n<meta property=\"og:description\" content=\"Hear from researchers and innovators leading the way at BrainTech 2025!\" \/>\n<meta property=\"og:url\" content=\"https:\/\/braintechaustralia.com.au\/2025\/speakers\/\" \/>\n<meta property=\"og:site_name\" content=\"BrainTech 2025\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-15T06:17:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/braintechaustralia.com.au\/2025\/wp-content\/uploads\/2025\/07\/braintech-2025-navy-bg-1200x800px.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"800\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"78 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/braintechaustralia.com.au\\\/2025\\\/speakers\\\/\",\"url\":\"https:\\\/\\\/braintechaustralia.com.au\\\/2025\\\/speakers\\\/\",\"name\":\"Speakers - BrainTech 2025\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/braintechaustralia.com.au\\\/2025\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/braintechaustralia.com.au\\\/2025\\\/speakers\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/braintechaustralia.com.au\\\/2025\\\/speakers\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/braintechaustralia.com.au\\\/2025\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/braintech-2025-navy-bg-1200x800px.jpg\",\"datePublished\":\"2025-06-16T01:57:13+00:00\",\"dateModified\":\"2026-06-15T06:17:02+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/braintechaustralia.com.au\\\/2025\\\/speakers\\\/#breadcrumb\"},\"inLanguage\":\"en-AU\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/braintechaustralia.com.au\\\/2025\\\/speakers\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-AU\",\"@id\":\"https:\\\/\\\/braintechaustralia.com.au\\\/2025\\\/speakers\\\/#primaryimage\",\"url\":\"https:\\\/\\\/braintechaustralia.com.au\\\/2025\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/braintech-2025-navy-bg-1200x800px.jpg\",\"contentUrl\":\"https:\\\/\\\/braintechaustralia.com.au\\\/2025\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/braintech-2025-navy-bg-1200x800px.jpg\",\"width\":1200,\"height\":800,\"caption\":\"BrainTech 2025\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/braintechaustralia.com.au\\\/2025\\\/speakers\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/braintechaustralia.com.au\\\/2025\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Speakers\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/braintechaustralia.com.au\\\/2025\\\/#website\",\"url\":\"https:\\\/\\\/braintechaustralia.com.au\\\/2025\\\/\",\"name\":\"BrainTech 2025\",\"description\":\"30 October 2025 \u2022 Melbourne\",\"publisher\":{\"@id\":\"https:\\\/\\\/braintechaustralia.com.au\\\/2025\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/braintechaustralia.com.au\\\/2025\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-AU\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/braintechaustralia.com.au\\\/2025\\\/#organization\",\"name\":\"BrainTech 2025\",\"url\":\"https:\\\/\\\/braintechaustralia.com.au\\\/2025\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-AU\",\"@id\":\"https:\\\/\\\/braintechaustralia.com.au\\\/2025\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/braintechaustralia.com.au\\\/2025\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/braintech-2025-logo-sf-300x28px.png\",\"contentUrl\":\"https:\\\/\\\/braintechaustralia.com.au\\\/2025\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/braintech-2025-logo-sf-300x28px.png\",\"width\":300,\"height\":28,\"caption\":\"BrainTech 2025\"},\"image\":{\"@id\":\"https:\\\/\\\/braintechaustralia.com.au\\\/2025\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Speakers - BrainTech 2025","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/braintechaustralia.com.au\/2025\/speakers\/","og_locale":"en_US","og_type":"article","og_title":"Speakers - BrainTech 2025","og_description":"Hear from researchers and innovators leading the way at BrainTech 2025!","og_url":"https:\/\/braintechaustralia.com.au\/2025\/speakers\/","og_site_name":"BrainTech 2025","article_modified_time":"2026-06-15T06:17:02+00:00","og_image":[{"width":1200,"height":800,"url":"https:\/\/braintechaustralia.com.au\/2025\/wp-content\/uploads\/2025\/07\/braintech-2025-navy-bg-1200x800px.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"78 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/braintechaustralia.com.au\/2025\/speakers\/","url":"https:\/\/braintechaustralia.com.au\/2025\/speakers\/","name":"Speakers - BrainTech 2025","isPartOf":{"@id":"https:\/\/braintechaustralia.com.au\/2025\/#website"},"primaryImageOfPage":{"@id":"https:\/\/braintechaustralia.com.au\/2025\/speakers\/#primaryimage"},"image":{"@id":"https:\/\/braintechaustralia.com.au\/2025\/speakers\/#primaryimage"},"thumbnailUrl":"https:\/\/braintechaustralia.com.au\/2025\/wp-content\/uploads\/2025\/07\/braintech-2025-navy-bg-1200x800px.jpg","datePublished":"2025-06-16T01:57:13+00:00","dateModified":"2026-06-15T06:17:02+00:00","breadcrumb":{"@id":"https:\/\/braintechaustralia.com.au\/2025\/speakers\/#breadcrumb"},"inLanguage":"en-AU","potentialAction":[{"@type":"ReadAction","target":["https:\/\/braintechaustralia.com.au\/2025\/speakers\/"]}]},{"@type":"ImageObject","inLanguage":"en-AU","@id":"https:\/\/braintechaustralia.com.au\/2025\/speakers\/#primaryimage","url":"https:\/\/braintechaustralia.com.au\/2025\/wp-content\/uploads\/2025\/07\/braintech-2025-navy-bg-1200x800px.jpg","contentUrl":"https:\/\/braintechaustralia.com.au\/2025\/wp-content\/uploads\/2025\/07\/braintech-2025-navy-bg-1200x800px.jpg","width":1200,"height":800,"caption":"BrainTech 2025"},{"@type":"BreadcrumbList","@id":"https:\/\/braintechaustralia.com.au\/2025\/speakers\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/braintechaustralia.com.au\/2025\/"},{"@type":"ListItem","position":2,"name":"Speakers"}]},{"@type":"WebSite","@id":"https:\/\/braintechaustralia.com.au\/2025\/#website","url":"https:\/\/braintechaustralia.com.au\/2025\/","name":"BrainTech 2025","description":"30 October 2025 \u2022 Melbourne","publisher":{"@id":"https:\/\/braintechaustralia.com.au\/2025\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/braintechaustralia.com.au\/2025\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-AU"},{"@type":"Organization","@id":"https:\/\/braintechaustralia.com.au\/2025\/#organization","name":"BrainTech 2025","url":"https:\/\/braintechaustralia.com.au\/2025\/","logo":{"@type":"ImageObject","inLanguage":"en-AU","@id":"https:\/\/braintechaustralia.com.au\/2025\/#\/schema\/logo\/image\/","url":"https:\/\/braintechaustralia.com.au\/2025\/wp-content\/uploads\/2025\/06\/braintech-2025-logo-sf-300x28px.png","contentUrl":"https:\/\/braintechaustralia.com.au\/2025\/wp-content\/uploads\/2025\/06\/braintech-2025-logo-sf-300x28px.png","width":300,"height":28,"caption":"BrainTech 2025"},"image":{"@id":"https:\/\/braintechaustralia.com.au\/2025\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/braintechaustralia.com.au\/2025\/wp-json\/wp\/v2\/pages\/2302","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/braintechaustralia.com.au\/2025\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/braintechaustralia.com.au\/2025\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/braintechaustralia.com.au\/2025\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/braintechaustralia.com.au\/2025\/wp-json\/wp\/v2\/comments?post=2302"}],"version-history":[{"count":7,"href":"https:\/\/braintechaustralia.com.au\/2025\/wp-json\/wp\/v2\/pages\/2302\/revisions"}],"predecessor-version":[{"id":3070,"href":"https:\/\/braintechaustralia.com.au\/2025\/wp-json\/wp\/v2\/pages\/2302\/revisions\/3070"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/braintechaustralia.com.au\/2025\/wp-json\/wp\/v2\/media\/2382"}],"wp:attachment":[{"href":"https:\/\/braintechaustralia.com.au\/2025\/wp-json\/wp\/v2\/media?parent=2302"}],"wp:term":[{"taxonomy":"dipi_cpt_category","embeddable":true,"href":"https:\/\/braintechaustralia.com.au\/2025\/wp-json\/wp\/v2\/dipi_cpt_category?post=2302"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}